

505,446  
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
12 September 2003 (12.09.2003)

PCT

(10) International Publication Number  
**WO 03/075003 A1**

(51) International Patent Classification<sup>7</sup>: **G01N 33/15**,  
33/92, A61K 35/12, 45/06, C12Q 01/00, A61P 29/00

(74) Agent: **MADDERNS**; Level 1, 64 Hindmarsh Square,  
Adelaide, S.A. 5000 (AU).

(21) International Application Number: **PCT/AU03/00266**

(22) International Filing Date: **3 March 2003 (03.03.2003)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:  
**PS 0821** **1 March 2002 (01.03.2002)** **AU**

(71) Applicants (for all designated States except US):  
**WOMEN'S & CHILDREN'S HOSPITAL** [AU/AU];  
72 King William Road, Nort Adelaide, S.A. 5006 (AU).  
**RURAL INDUSTRIES RESEARCH AND DEVELOPMENT CORPORATION** [AU/AU]; Level 1, AMA  
House, 42 Macquarie Street, Barton, ACT 2600 (AU).  
**EMU INDUSTRY FEDERATION OF AUSTRALIA INCORPORATED** [AU/AU]; PO BOX 57, Wagin, W.A.  
6315 (AU).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report

(72) Inventor; and

(75) Inventor/Applicant (for US only): **FERRANTE, Antonio** [AU/AU]; 59 Gleneagles Road, Mount Osmond, S.A. 5064 (AU).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **THERAPEUTIC PROPERTIES OF OILS**

(57) Abstract: The present invention provides a novel scientific approach to determine whether a compound has anti-inflammatory activity. In particular, the novel assays allow the screening of compounds for the purposes of prophylactic and therapeutic use in treating or ameliorating the symptoms of T-cell, macrophage or neutrophil mediated diseases in mammals. In particular, the invention is based on the measurement of the capacity of a substance being an oil or fat, an alcoholic extract of an oil or fat, a biologically active component of an oil or a fat, or a preparation comprising an oil or fat, to suppress the activity of T-cells, macrophages or neutrophils in humans or animals in response to chemical and/or biological agents that activate these cell types. Measurements are made either *in vivo* (eg in mice) or in an *in vitro* preparation of human T-cells, macrophages or neutrophils or a cell line derived therefrom. The substance is, in particular, emu oil or an ethanolic extract thereof. Therapeutic compositions and methods are also disclosed.

WO 03/075003 A1

## THERAPEUTIC PROPERTIES OF OILS

### BACKGROUND OF THE INVENTION

The immune system plays a critical role in the prevention of disease and the maintenance of health.

Diminished immune function, as occurs in the aged, in children under the age of two years, and in burns patients, as well as patients undergoing chemotherapy or transplantation, can increase the risk of disease.

On the other hand, inappropriate or excessive response of the immune system to infective agents or various stressors can result in tissue damage. Accordingly, autoimmune and allergic inflammatory diseases continue to be a major burden to the community. These diseases result from the "inappropriate" stimulation of leukocytes of the immune system, which include lymphocytes, macrophages and neutrophils. For example, chronic immune system activation can increase the risk of disease, eg arthritis, cystic fibrosis, inflammatory bowel disease, Crohn's disease, graft versus host disease, multiple sclerosis (MS), systemic sclerosis, allergic contact dermatitis, psoriasis and diabetes. The main approaches to treating these diseases are to depress the immunological reactions by inhibiting a variety of responses of leukocytes (1).

There are numerous reports showing that animal and plant fats and oils have therapeutic properties through their ability to modulate immune function; eg fish oils, flaxseed oil, linseed oil, borage oil, emu oil and evening primrose oil.

The Australian aboriginal practice of external application of emu oil for treating aches and pains has provided anecdotal evidence for the anti-inflammatory properties of this oil (2,3). However, conclusive scientific evidence for the *in vivo*

efficacy of anti-inflammatory properties of emu oil is lacking, with only limited studies in experimental arthritis in rodents having been conducted thus far (4,5).

It is well appreciated in the emu oil industry that the anti-inflammatory efficacy of different preparations of emu oil varies significantly. This variation can be so significant that it hampers the therapeutic use of this oil (6) and hence its commercial value. At the moment, no standard protocols are followed in the farming or source of emu, the part of the bird from which the oil is obtained, the method of preparation or storage of emu oil (7). In fact, there are conflicting data on the therapeutic efficacy of different emu and other oils and there appear to be at least two reasons for this.

Firstly, most animal fats and oils are complex mixtures with highly variable chemical compositions. The individual components almost certainly have different effects on immune function and may, in addition, inhibit the activities of other components or even synergise with each other.

Secondly, the immune system is made up of a number of different cell types, each with highly specific roles and not all of which respond in the same way to fats and oils. Optimum activity of an oil is therefore dependent on the condition being treated, as the cell types each have defined roles.

Furthermore, current scientific assays and tests on the efficacy of oils have presented conflicting results. The inability to quality control and standardise the oil for anti-inflammatory properties has posed a major limitation to the use of emu oil as a therapeutic agent. Variations in these factors can, in part, contribute to variations in the efficacy of the oil and have prevented its use in humans as a pharmaceutical agent, more particularly as a treatment for inflammatory diseases, conditions or responses.

A accurate assessment of the immunosuppressive activity prior to therapeutic use would greatly increase the consistency and reproducibility of treatment with a particular oil, as well as providing a means of increasing its therapeutic activity.

Unfortunately, the prior art is lacking in methods of assessing the likely therapeutic activity of an oil sample.

The present inventors have developed a method of measuring the intrinsic capacity of an oil to suppress the immune system of humans and animals. The method also allows the testing of the level of therapeutic activity of an oil, thereby enabling differentiation between oil samples of low and high therapeutic activity, and enabling oils to be graded for their therapeutic activity.

### SUMMARY OF THE INVENTION

According to one aspect, the present invention overcomes or reduces at least some of the above-mentioned problems by providing a novel scientific approach to accurately determine whether a compound has anti-inflammatory activity. In particular, the novel assays allow the screening of compounds for the purposes of prophylactic and therapeutic use in treating or ameliorating the symptoms of T-cell, macrophage or neutrophil mediated diseases in mammals.

In particular, the invention is based on the measurement of the capacity of an oil or fat, alcoholic extracts of an oil or fat, biologically active components of an oil or a fat, or preparations comprising oils or fats, to suppress the activity of T-cells, macrophages or neutrophils in humans or animals in response to chemical and/or biological agents that activate these cell types. Measurements are made either in mice (ie in vivo) or in human T-cells, macrophages or neutrophils isolated from blood. The method can be used to quantify the total T-cell, macrophage and/or neutrophil suppressive activities per unit mass or volume in any oil or fat and the degree of suppression of T-cell, macrophage or neutrophil responses by an oil or fat.

Using a model representative of a *chronic* inflammatory reaction (the delayed type hypersensitivity (DTH) reaction), emu oil was found to inhibit T lymphocytes and macrophage recruitment to the site of inflammation.

Emu oil was also found to significantly suppress the *acute* inflammatory response induced by Carrageenan reaction. Alcoholic, and in particular ethanolic, soluble fractions of emu oil were found to inhibit the ability of neutrophils to adhere to endothelial cells, but in particular were found to substantially suppress the chemotactic response of neutrophils.

The effects of emu oil and its ethanol soluble components on T-cell, macrophage and neutrophil chemotaxis and recruitment indicate that both emu oil and its ethanol soluble components are useful for treating acute and chronic inflammatory reactions.

After dissolving emu oil in ethanol, the soluble fraction of emu oil (containing primarily triglycerides) was found to have anti-inflammatory properties and contradicts the earlier belief that emu oil by itself does not have anti-inflammatory properties. The inventors have conclusively shown that the ethanol soluble fraction of the emu oil suppresses T-lymphocyte activity in that it suppresses both lymphoproliferation and also the production of pro-inflammatory and pro-DTH cytokines such as interleukin-2, lymphotoxin and interferon- $\gamma$ . These activities of T-lymphocytes play fundamental roles in inflammation. Further fractionation of the ethanol soluble fraction showed that certain components contributed to anti-inflammatory activity, whilst others suppressed anti-inflammatory activity.

The inventors also found that the efficacy of the anti-inflammatory properties of the emu oil was dependent on the temperature at which the oil was rendered from emu fat. Activity was found with oils rendered at temperatures of 60°C and 80°C, and ever better activity with oils rendered at 100°C. However, preparations prepared at 40°C had minimal activity.

According to a first aspect of the invention, there is provided an assay system for testing samples of substances (such as emu oils and other oils) to assess, in a

standardized manner, the anti-inflammatory activity of each sample, and to enable different samples to be graded in terms of anti-inflammatory activity (if any).

The assay system may involve administration of serially reducing amounts of the test substance (eg serially diluted in ethanol) to test animals (eg mice).

Administration may be by injection (eg into the footpad), or be intraperitoneal, topical or oral administration.

In one embodiment of the invention, the assay system comprises assessing the anti-inflammatory activity of a compound or composition, herein referred to as the test substance, by

- (i) injection of a suitable antigen into an appropriate body part (eg footpad) of a mammal, for example a mouse;
- (ii) either injection of a predetermined amount of said test substance into the same body part, or topical application to said mammal of a predetermined amount of said substance;
- (iii) measurement of the degree to which swelling which would otherwise result from injection of said antigen is reduced or alleviated, for example in either the footpad or the immune system organs (eg lymph nodes); and
- (iv) comparing the activity of said test substance, as measured in step (iii), against the activity of a standard compound having known anti-inflammatory characteristics, the activity of said standard compound having been measured by this same assay system of steps (i) to (iii), and having been used to generate a grading system to compare the efficacy of various test substances.

The antigen may, for example, be Carrageenan or sheep red blood cells (SRBC), and the test substance may be an emu oil or other oil believed to have anti-inflammatory activity.

In step (i), it is preferred that the antigen is injected either intraperitoneally or into the footpad or ear of a mouse. In step (ii), it is preferred that the test substance is injected intraperitoneally or applied topically.

The measurement of step (iii) is preferably undertaken some time, and in particular about 24 hours, after injection of the test substance (step (ii)).

An alternative, *in vitro* assay system for testing a substance so as to assess, in a standardised manner, its anti-inflammatory activity comprises:

- (i) measurement of the activity of an *in vitro* preparation of T-cells, macrophages or neutrophils, or a cell line derived therefrom;
- (ii) addition of said substance to said preparation of T-cells, macrophages or neutrophils, or said cell line derived therefrom;
- (iii) measurement of the change in activity of said preparation of T-cells, macrophages or neutrophils, or said cell line derived therefrom, following addition of said substance in step (ii); and
- (iv) comparing the change in activity (as measured in step (iii)) for said substance against the change in activity for a standard compound having known anti-inflammatory characteristics, the change in activity for the standard compound having been measured by this same assay system of steps (i) to (iii), and having been used to generate a grading system to compare the efficacy of various test substances.

This *in vitro* assay system may involve treating the preparation of T-lymphocytes, macrophages or neutrophils, or said cell line derived therefrom, with serially reducing amounts of the test substance, eg serially diluted in ethanol.

This assay system is a means for assessing the effect of the oil being tested on the cell (eg T-cell, macrophage or neutrophil) mediated immune response elicited by an antigen, and hence assessing its anti-inflammatory activity.

The following are examples of the types of *in vitro* assays which can be carried out, according to this assay system:

- (a) using a preparation of T lymphocytes, and measuring lymphoproliferation;
- (b) using a preparation of T lymphocytes, and measuring their production of cytokines, such as interleukin-2 (IL-2), tumor necrosis factors (eg TNF  $\alpha$  and lymphotoxin (TNF  $\beta$ )) and interferon  $\gamma$  (IFN- $\gamma$ );
- (c) using a preparation of neutrophils, and measuring their chemotatic activity; and
- (d) using a preparation of neutrophils, and measuring their adherence to endothelial cells.

T-cells play a major role in the tissue damage in various diseases, largely through their production of cytokines. Cytokines (such as TNF  $\alpha$  and IL-2) produced by T-cells are believed to contribute to the tissue damage resulting from abnormal immune function.

The use of therapeutic agents, preferably agents that are not toxic, to inhibit the production of cytokines by T-cells would be particularly useful in the treatment of tissue damage, particularly those mediated by T-cells.

Prior art agents used to treat T-cell mediated diseases are either toxic or have considerable systemic effects.

The present inventors have developed a method of treating or preventing tissue damage using (in particular) emu oil, a non-toxic material produced from the adipose tissue of emus. The inventors have developed a method of increasing the activity of the emu oil used for this purpose, thereby ensuring reliability and



consistency of the product and, moreover, have found that permeants (substances used to increase the movement of chemical substances through the skin) are not required for activity. The inventors have also found that an alcoholic extract of emu oil so produced is also effective in treating T-cell mediated diseases.

The invention also relies on the discovery that emu oil, and alcoholic extracts of emu and other oils, are able to suppress the activity of T-cells, being cell types that contribute to the tissue damage in a variety of human diseases. The invention involves the use of emu and other oils, as well as extracts thereof, to treat these different disease states by preventing or reducing the damage caused by T-cells. The use of emu oil has a further advantage in that it can also reduce the tissue damage caused by another important immune cell type, the neutrophil.

Therefore, according to a second aspect of the invention, there is provided a composition comprising emu oil, or a biologically active extract or component thereof, optionally together with a carrier vehicle, for treating or ameliorating the symptoms of T-cell mediated diseases or conditions or neutrophil mediated diseases or conditions in mammals. Examples of the diseases or conditions include immune complex disease, renal disease, nephritis, arthritis (eg rheumatoid arthritis or septic arthritis), glomerulitis, vasculitis, gout, urticaria, angioedema, cardiovascular disease, systemic lupus erythematosus, breast pain/premenstrual syndrome, asthma, neurological disease, attention deficit disorder (ADD), psoriasis, retinal disease, acne, sepsis, granulomatosis, inflammation, reperfusion injury, cystic fibrosis, adult respiratory distress syndrome, thermogenesis, diabetes, inflammatory bowel disease, Crohn's disease, multiple sclerosis (MS), systemic sclerosis, osteoarthritis, atopic dermatitis, allergic contact dermatitis, graft rejection (graft versus host disease) or transplantation.

The composition can be in the form of an oral, injectable or topical composition. The biologically active extracts or components include at least one of the following: triglyceride fractions or triglyceride fraction components, sterol fractions or sterol fraction components, phenolic fractions or phenolic fraction components, alkali-

stable fractions or alkali-stable fraction components, organic solvent extracts (eg of emu oil) or components thereof. In the preferred form, the organic solvent is ethanol.

According to a third aspect of the invention, there is provided a method of treating or ameliorating the symptoms of T-cell mediated diseases or conditions or neutrophil mediated diseases or conditions in mammals, the method comprising administering an effective dose of a composition comprising emu oil, or a biologically active extract or component thereof (eg as exemplified above).

The composition can be administered orally, parenterally (eg by injection) or topically.

It is preferred that said effective dose of said composition be administered after or just before a T-cell mediated disease or condition, neutrophil mediated disease or condition or inflammation reaction has occurred.

In a fourth aspect of the invention, an alcohol (such as ethanol), is used to extract compounds having anti-inflammatory activity from the emu oil or other biologically active oil or fat. Alternative organic solvents which would perform the same function of solubilising and extracting effective compounds from the oil would be apparent to persons skilled in the art.

Although emu oil is specifically exemplified, it is to be understood by those skilled in the art that the assays, methods and compositions of the present invention can be applied to any substance or oil of which emu oil is but one example. Other suitable oils are, for example, other animal oils; plant oils, such as tea tree oil, flaxseed oil, linseed oil, borage oil or evening primrose oil; fish oils; and algal, microbial and fungal oils.

According to a fifth aspect of the invention, there is provided a method of preparing or rendering emu oil for therapeutic use in a mammal, including the step

of heating the emu oil, or the tissue from which the emu oil is derived, to a temperature of at least 40°C.

As used throughout the present specification and claims, the term "biologically active" refers to the capacity to elicit an anti-inflammatory response.

#### DETAILED DESCRIPTION OF THE INVENTION

The active ingredient(s) in emu oil that is (are) responsible for the reported anti-inflammatory activity has (have) not been identified. Emu oil is composed mainly of triglycerides that contain varying amounts of fatty acids (Table 1). The limited available data on the composition of emu oil suggest that the clear oil can vary markedly in terms of anti-oxidants (carotenoids, flavonoids), skin permeation-enhancing factors and  $\alpha$ -linolenic acid (18:3 $\omega$ 3) (from 0-20%) (4) content. The finding that the oil is not rich in  $\omega$ 3 fatty acids makes it unlikely that the anti-inflammatory effect of the oil is related to  $\omega$ 3 fatty acids, which are widely perceived as having anti-inflammatory actions. A previous study has reported, as unpublished results, that the efficacy of emu oil as an anti-inflammatory agent did not correlate with  $\omega$ 3 fatty acid content (0.2-19.7%) of the oil (4).

Table 1. Fatty acid composition of emu oil

COMPONENT	AMOUNT
Oleic acid (18:1 $\omega$ 9)	47-58%
Palmitic acid (16:0)	19-24%
Stearic acid (18:0)	8-11%
Linoleic acid (18:2 $\omega$ 6)	5.5-17%
Hexadecenoic acid (16:1 $\omega$ 7)	3-6%

A combination of Thin Layer Chromatography (TLC), Gas Chromatography (GC) and Gas Chromatography-Mass Spectroscopy (GC-MS) analyses demonstrated the presence of a wide range of fatty acids, sterols and phenols in emu oil preparations. From the TLC, it was evident that triacylglycerol is the major component and needs to be considered as one of the anti-inflammatory components of the oil since previous studies have shown that fatty acids can inhibit inflammation.

In terms of its phenolic content, Makin emu oil was found to have  $25\mu\text{mol/l}$  which is about 20 fold less than the level of phenols in olive oil. Thus, it is unlikely that this is the active anti-inflammatory element of emu oil since olive oil has been reported not to have anti-inflammatory properties (7) (also, our unpublished observations).

Sterol analyses revealed that emu oil was similar to tuna oil but substantially different from olive oil, with cholesterol making up the major component of the emu oil sterols. The role of these substances in the anti-inflammatory properties of emu oil was not evaluated.

The fatty acid composition of the oil was analysed independently by three different groups using GC-MS, MS and GC. From these studies, it was found that the major fatty acids are oleic (around 50%), palmitic (around 20%), stearic (around 10%), linoleic (around 10%) and palmitoleic (around 5%). These could be taken as the main fatty acid components of Australian emu oils. The composition of oils prepared from emus in different geographical locations and probably prepared in different ways were not distinguishable based on the fatty acid content analyses.

Extensive studies using a standard emu oil (Makin) demonstrated that, when administered to mice, the oil consistently caused depression of chronic and acute inflammation. For chronic inflammation, a standard delayed type hypersensitivity reaction (DTH), which is induced and elicited by SRBC antigens, was used. The reaction was measured by monitoring the amount of hind footpad swelling as a result of an antigen challenge. Makin emu oil significantly inhibited the elicitation of this inflammatory response. Since the cells involved are predominantly T lymphocytes and macrophages, an effect, either directly or indirectly, on the accumulation of these cell types must have been caused by the administration of emu oil. The effects of emu oil were not restricted to chronic inflammation, since it was just as effective in depressing carrageenan-induced inflammation, considered

to be a model for testing acute inflammation and which primarily involves neutrophil accumulation at the injected site.

Using the chronic inflammatory model of DTH, the effects of different preparations of emu oil on this response were examined in an effort to explain the reasons for variability in the efficacy of the different preparations. Of the samples of emu oil examined, Makin emu oil was the most effective. Toowoomba and Little Meadow showed some anti-inflammatory activity, less was seen with emu oil A2-100G and none with emu oil G53. This could not be explained on the fatty acid composition of the emu oil samples, since these were essentially similar (Tables 5 and 6 on pages 29 to 30).

Examination of the characteristics of the depressive effects of emu oil on inflammation showed that the oil was most effective when given close to or just after the antigen challenge. This was shown by the fact that the efficacy of the emu oil was greatest when the oil was given 1h before, rather than 5h before, challenge. A similar effect was shown using the carrageenan-induced inflammation model. It was also found that, when the emu oil treatment was delayed to 3h after the elicitation of the inflammatory response, the efficacy of the emu oil was significantly more effective than treatments given 1h before challenge. Firstly, this suggests that the oil acts quite rapidly on components of the immune system; secondly, this shows that inflammation can be controlled using suitably prepared emu oil even after an individual begins to experience inflammation.

Rendering temperature was found to govern the efficacy and/or type of oils produced since emu oil extracted at 40°C was found to be less active than when it was extracted at 60°C, 80°C or 100°C. No evidence was found in terms of fatty acid composition by GC analysis between the oils produced at the latter three different temperatures since these were very similar in content, including the levels of linoleic acid (18:2 $\omega$ 6) (see, for example, Table 11 on page 40).

To identify the components in emu oil responsible for the anti-inflammatory effects, the emu oil was added directly to cultured lymphocytes and neutrophils in order to see if the activities of these leukocytes would be altered. The studies were unsuccessful because of the solubility problem of the oil. To overcome this problem, the oil was solubilised in ethanol and, following fractionation, the components having anti-inflammatory activity were identified (see Fig 28). The solubilised fraction had significant anti T lymphocyte activity. Since T lymphocytes are the major cell which mediate the DTH reaction and chronic inflammation, these results show that emu oil is able to suppress DTH activity. Chemical analysis of the ethanol fraction by GC did not reveal any enrichment of a particular fatty acid, although there was, however, a slight increase in the proportion of 18:2 $\omega$ 6. Thus, the ethanol soluble fraction may be a source from which the active components can be used to treat inflammation. Interestingly, the anti T cell activity in terms of inhibition of lymphoproliferation in the emu oil preparations rendered at 40°C, 60°C and 80°C correlated with their *in vivo* activity with inhibition of DTH activity. The inventors have shown that, in both instances, rendering temperature of 60°C < T  $\leq$  100°C produces more efficacious oils than rendering at 40°C (Fig 15 of Fig 17).

Further evidence for an effect on the T cell responses was shown by examining the effects of the ethanol soluble emu oil fraction on the cytokine products produced by activated T lymphocytes, IL-2, lymphotoxin, TNF  $\beta$  and IFN- $\gamma$ . Production of these cytokines was inhibited by pre-treating T lymphocytes with the solubilised emu oil fraction. The effects were extended to production of TNF by monocytes via LPS stimulation. However, it was evident that the T cell production of cytokines was more sensitive to emu oil than TNF production by monocytes, showing a preferential effect of the ethanol soluble emu oil fraction for T lymphocyte responses, suggesting the T cell as a major target for emu oil therapy.

The solubilised fraction of Makin emu oil was found to inhibit both chemotactic migration as well as adhesion of neutrophils to endothelial cells. Both of these

properties are key functions necessary for infiltration of neutrophils to sites of inflammation. Neutrophil adherence was also affected when endothelial cells were pre-treated with the solubilised fraction. The combination of the effects of the solubilised fraction on the neutrophils and endothelial cells would inhibit adherence of leukocytes to endothelial cells *in vivo*. While the effect on neutrophils is not relevant to DTH, it is highly relevant to carrageenan induced or acute inflammation, where the neutrophil is thought to be a key player (9).

The emu oil ethanol soluble fraction was found to be rich in free fatty acids (see Table 13 on page 45). Thus, one of the effects on T lymphocytes could involve fatty acids such as 18:2 $\omega$ 6. The inventors' investigations established that serum fatty acid binding proteins such as albumin can decrease the activity of free fatty acids by binding to them. Further investigations were conducted as to whether or not serum could abrogate the effects of a Makin emu oil ethanol extract, which had been rendered at 40°C. The addition of serum was found to block most of the anti-T cell activity of this oil fraction and this would explain the discrepancies and variations in efficacy of emu oils to treat inflammation.

On TLC separation of the ethanol soluble fraction (see Fig 27), several distinct bands were seen and at least one corresponded to the migration of the 18:2 $\omega$ 6 which was shown to be responsible for the majority of anti-T cell activity. However, other fractions were also active, suggesting that several emu oil components might be responsible.

The data from the experimental section below have revealed avenues which could be used to standardise emu oil, particularly for its anti-inflammatory activity. The results indicate that mice may be used as models of testing systems for chronic (DTH) and acute (carrageenan) inflammatory diseases. These represent simple systems in which inflammation can be readily quantified. To decrease variability, an ip route rather than topical emu oil administration is used. It has been established that the efficacy of an emu oil preparation may be determined by

establishing the extent to which the preparation can be diluted before anti-inflammatory activity is lost. In this system of standardisation, an established, active emu oil can be used as a standard against which other emu oils may be tested. A criterion for accepting or rejecting emu oil preparations can then be established for the industry. The standard can be based on the optimal rendering conditions, as well as storage of oils, feed for emus, breed of emu etc (Table 2). Oil prepared at 100°C was found to have the highest anti-inflammatory activity, whilst oil prepared at 40°C had minimal activity.

Furthermore, the inventors found that the anti-inflammatory activity of emu oil was strongest when administered after inflammation had occurred. Also, the inventors found that administration of the emu oil 1h prior to inflammation has better anti-inflammatory efficacy than if the oil is administered 3h prior to inflammation.



**Table 2      PREPARATION OF EMU OIL (potential causes of variability)****Collection of fat**

- Age of animal
- Diet
- Genetics
- Sex
- Length of time after death of the animal
- Storage conditions of collected fat
- Lipase/phospholipase/lipoxygenase activity
- Non-enzymic oxidation

**Rendering**

- Temperature of rendering
- Type of container used
- Amount of water
- Surface area
- Length of rendering time

**Filtration**

- Temperature of filtration
- Type of filter
- Water in the filtrate
- Metal content
- Protein content
- Variable crystallisation

**Possible products formed during the processing of emu fat**

- Oxidation products of fatty acids
- Free fatty acids
- Lysophospholipids
- Conjugated linoleic acid
- Trans isomers
- Diglycerides
- Monoglycerides
- Oxidation products of cholesterol

---

It is preferable to extend the testing by conducting *in vitro* assays to support the data from the *in vivo* chronic and acute inflammation reactions. This is particularly important before the oils can be commercially used. Thus, effect on T lymphocyte and monocyte function for chronic, and neutrophil function for acute, inflammation can be employed. A model is illustrated in Fig 2.

Both for the DTH and carrageenan inflammatory response, a relationship can then be established for the amount of oil versus the degree of inhibition of inflammation.

From the graph of Fig 1, the emu oil concentration required to achieve 25% inhibition ( $ID_{25}$ ) of the inflammatory responses can be deduced. From this value, the anti-inflammatory power of the oil can be determined. The values may be computed for both acute and chronic inflammation, where they may be different.

The above anti-inflammatory efficacy values can be corroborated by data using the ethanol soluble fraction of the oil, examining an effect on T lymphocyte function and neutrophil function. Two useful parameters are lymphoproliferation for T lymphocytes and chemotaxis for neutrophils for chronic and acute inflammation respectively. Similar  $ID_{25}$  and maximal inhibition values based on these parameters can be computed as discussed above.

Based on the effects of emu oil on T lymphocyte and macrophage responses, as well as neutrophil responses, the therapeutic potential is apparent for diseases/conditions summarised in Table 3. The targets in the treatment of these inflammatory diseases are outlined, specifically those which are critical and are targeted by emu oil. The targets of emu oil have been further expanded in Fig 2, which shows the events which lead to joint damage in rheumatoid arthritis. The T cells and macrophages, as well as neutrophils, are targeted and either prevented from migrating into the tissue and/or prevented from being activated to generate tissue destructive mediating cytokines.

**Table 3 Therapeutic target for emu oil and the respective disease**

CONDITION/DISEASE	TARGETS RELEVANT TO EMU OIL THERAPY
Cardiovascular diseases	Endothelial cells, macrophages
Rheumatoid arthritis	T cells, macrophages and neutrophils
Atopic dermatitis	T cells, interferon $\gamma$
Inflammatory bowel disease	T cells, macrophages, neutrophils
Systemic lupus erythematosus	T cells and macrophages
Asthma	T cells, macrophages, neutrophils, cytokines
Cystic fibrosis	Macrophages and neutrophils
Breast pain/premenstrual syndrome	Oedema
Transplantation	T cells, cytokines
Neurological diseases	T cells, macrophages
Psoriasis	T lymphocytes, interferon $\gamma$
Diabetes renal, retinal and cardiovascular complications	Endothelial cells, macrophages, neutrophils
Gout	Neutrophils
Acute respiratory distress syndrome	Neutrophils, cytokines
Acne	Neutrophils, cytokines
Septic arthritis	Neutrophils, cytokines
Reperfusion injury	Neutrophils, cytokines

In summary, the data herein has shown the complexity of the composition of emu oil, in which the fatty acid content was studied in detail. There are no major differences in the levels of the various fatty acid species in distinctly different preparations, in terms of geography, feed, rendering and storage. Nevertheless, there is a marked difference in the ability to depress inflammation. Using a freshly prepared standardised emu oil preparation (Makin), the anti-inflammatory properties of emu oil were tested, in chronic and acute *in vivo* and *in vitro* inflammation models. Some evidence points to at least some of the activity being due to an unsaturated fatty acid, 18:2 $\omega$ 6, but the study has demonstrated the difficulty in trying to identify what gives rise to the anti-inflammatory properties. Be that as it may, the inflammatory models developed can be used to standardise the anti-inflammatory activity of emu oil, which would seem to be a prerequisite for developing a viable industry, using quality-controlled Australian oils.

## Materials and Methods

### Emu oils

Details of the emu oils used in the study are outlined in Table 4. The emu oils were kept frozen at -20°C in aliquots.

**Table 4** Description of the different preparations of emu oils used in the present study

	Rendering Process	Age of Oil	Age of birds at slaughter	Feed
Makin	Back fat @ 40C	2 months	1-15 months old	Feed lot mix
G53	Gut fat @ 40C	4 years	1-3 years old	Grainfed & range
A2-100G	Gut fat @ 40C	4 years	5-3 years old	Grainfed & range
Toowoomba	Back fat @ 40C	4 years	2-3 years old	Grainfed & range
Little Meadow	Gut & back fat @ 104C	2 years	Unknown	Emu pellets & range
Gut Fat A	Gut fat rendering temperature unknown	1 year	1-15 months old	Farmed: Green clovers, weeds & grasses, milled barley, tritcala, wheat & lucerne, canola oil
Back Fat A	Back fat rendering temperature unknown	1 year	1-15 months old	
Gut Fat B	Gut fat rendering	1 year	1-15 months old	
Back Fat B	Back fat rendering temperature unknown	1 year	1-15 months old	
Commercial	Unknown	Unknown	Unknown	Unknown

## 1. Preparation of ethanol soluble/insoluble fractions

To obtain the ethanol soluble fraction, 2ml of emu oil was mixed with 1ml of ethanol, centrifuged at 2,500g/3 min/4°C and the upper phase collected. The extraction procedure was repeated three times on the lower phase. These ethanol soluble fractions were pooled, centrifuged and dried under N<sub>2</sub> gas stream. Eventually, stocks of 2ml volume were made for experiments; also, the ethanol insoluble fraction (EIF) remaining was retained as a rich source of triglyceride.

## 2. Fatty acid analyses

### 2.1 Thin layer chromatography

Up to 1mg emu oil in 20-40µl chloroform-methanol (4:1) was applied as a 1cm band to the edge of a TLC plate. Linoleic acid (18:2) was applied as a standard in a 0.5 cm band to one side of the test sample. The chromatogram was developed in hexane-ether-acetic acid (80:20:1) and dried in the fume hood. The zones were viewed by exposure to I<sub>2</sub> vapour or sprayed lightly with 18N H<sub>2</sub>SO<sub>4</sub> and charred at 150°C. Larger amounts of Makin emu oil were dissolved in chloroform-methanol (4:1), and aliquots of the solution (equivalent to 5 mg of oil) were applied as a 6-7 cm band to a silica thin layer plate. An equivalent amount of olive oil dissolved in the same solvent mixture was applied to the plate as a 6-7cm band and served as a control. An unesterified fatty acid standard was applied to the edges of the plate.

A chromatogram was developed in hexane-ether-acetic acid (80:20:1) and, after drying, the plate was exposed to iodine vapour.

## 2.2 NMR analysis

This was performed by Dr N.Trout, Flinders University. To a dry flask (5ml) was added 100-120 mg of the thawed emu oil (shaken thoroughly), which was dissolved in dry toluene (1-1.2 ml). To this was added a freshly prepared solution of sodium methoxide (75mg Na in methanol (2ml)) under N<sub>2</sub>. The resulting mixture was placed under reflux for ninety minutes, before cooling and adding acetic acid (100µl) and water (2.5ml). The white mixture was extracted with hexane twice before the layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and the volatiles removed *in vacuo*. <sup>13</sup>C and <sup>1</sup>H NMR measurements were recorded on a Varian Gemini FT 300 MHz multinuclear spectrometer, operating at 75.46 MHz and 300.75 MHz respectively. All samples were dissolved in deuterated chloroform, using the central peak (77.0ppm) for <sup>13</sup>C and CHCl<sub>3</sub> (7.26 ppm) for <sup>1</sup>H NMR referencing. To a NMR tube was added 75-100 mg of the emu oil followed by deuterated CDCl<sub>3</sub> (0.8ml). The resulting solution was analysed by NMR. After one hour of pulsing, the spectrum was printed to show all the signals indicative of a triglyceride.

## 2.3 GC Analyses

*Child Health Research Institute (Dr. R. Gibson/Mr. M. Neumann):* One drop of emu oil was methylated in 5 ml of 1% sulphuric acid (36N) in methanol for 2 hours at 70°C. After cooling, the resulting methyl esters were extracted into 2 ml of n-heptane and transferred to vials containing anhydrous sodium sulphate as the dehydrating agent. Emu oil fatty acid methyl esters were separated and quantified using a Hewlett-Packard 6890 gas chromatograph equipped with a 50m capillary column (0.33mm ID) coated with BPX-70 (0.25µm film thickness - SGE Pty Ltd, Victoria, Australia). The injector temperature was set at 250°C and the flame ionisation detector at 300°C. The initial oven temperature was 140°C and was programmed to rise to 220°C at 5°C per minute. Helium was used as the carrier gas at a velocity of 35cm per second. Fatty acid methyl esters were identified based on retention time to authentic lipid standards from Nuchek Prep Inc (Elysian, MN).

*RMIT (Prof. A. Sinclair/Ms. K. Murphy):* Samples were analysed in duplicate. An aliquot of whole lipid was taken and dried using a stream of nitrogen. Samples were hydrolysed to free fatty acids using 7.9% KOH (Univar, AJAX chemicals, Australia) in methanol (Merck, Germany). Samples were cooled and converted to fatty acid methyl esters (FAME) using 20% boron trifluoride (BF<sub>3</sub>) in methanol complex (Merck, Germany). Gas Chromatographic analyses were performed using a Shimadzu GC 17A GC fitted with a flame ionisation detector (FID). FAME were analysed using a BPX-70 50m cross-linked 70% Cyanopropyl Polysilphenylene-siloxane capillary column with an ID of 0.32 mm and 0.25µm film thickness. Samples were injected at 125°C and held for 1.0 minute. The oven temperature was set to increase by 5°C/ min to 170°C and held for 4 minutes, then by 0.5°C/min to 175°C and 4°C/min to a final temperature of 220°C which was held for 3 minutes. The injector and detectors were maintained at 260°C and helium was used as the carrier gas. Peak area and concentrations were quantified on an IBM compatible computer using Shimadzu software (Japan).

#### 2.4 GC-MS

GC-MS analysis was performed on a Varian Saturn 4D instrument with a J&W DB 5% phenylmethylpolysiloxane column (30m x 0.25mm id).

#### 2.5 MS

*Women's and Children's Hospital (Dr. D. Johnson):* 1mg of emu oil was treated with benzene/methanol/acetyl chloride at 100°C for 90min. After cooling, the neutralised solution was extracted with hexane and samples of the extract were injected into a Perkin Elmer Turbomass Mass Spectrometer.

### 3. Sterol analysis

These experiments were carried out by Ms K Murphy from the laboratory of Professor A. Sinclair at the Royal Melbourne Institute of Technology. Sterol-enriched fractions were obtained from two emu oil samples (Makin and G53) by alkaline saponification with 5% KOH in methanol/water (80:20, v/v), followed by

extraction with 2 ml of hexane:chloroform (4:1, v/v) three times. The sterols were then converted to their corresponding trimethylsilyl ethers (OTMSi) with BSTFA (N,O-Bis (trimethylsilyl) trifluoroacetamide) for 15 minutes at 70°C. Gas chromatographic analyses were performed using a Shimadzu GC 17A GC fitted with a FID and a BPX-5 50m (5% Phenyl Polysilphenylene-siloxane) with an ID of 0.32mm and 0.25 µm film thickness. Samples were injected at 200°C and held for 1 minute. The oven temperature was set to increase by 20°C/min to 340°C and held for 30 minutes. The injector and detector were maintained at 280°C and helium was the carrier gas. Peak area and concentrations were quantified on an IBM compatible computer using Shimadzu software (Japan).

#### 4. Analysis of phenolics

The analysis of phenolics in a sample of Makin emu oil, in two other emu oils, and in a number of other fats and oils was carried out in the laboratory of Dr P. Hayball at the University of South Australia. The total phenolic content was determined using a modification of the Folin-Ciocalteu method and results were expressed as gallic acid equivalents.

#### 5. Inflammation models

**5.1 Delayed type hypersensitivity (DTH) reaction:** The DTH response was induced in 12 week old female BALB/c mice (Animal Resource Centre, Perth) as described previously (8). Briefly, mice were injected with sheep red blood cells (100µl of 10% haematocrit) (SRBC; Sigma Chemical Co.). After 5 days, the animals were challenged intradermally in the right hind footpad with SRBC (25µl of 40% haematocrit) or into the left footpad with diluent (25µl). The DTH response was determined 24 h post challenge and was calculated by comparing the thickness between the diluent vs SRBC injected footpads. Footpad thickness was measured with a dial calliper.

**5.2 Carrageenan-induced paw reaction:** Carrageenan-induced paw reaction was induced as described previously (9,10). Mice were inoculated with carrageenan (1

ml/kg of a 1% solution) (Type IV; Sigma Chemical Co.) into the right hind paw. The reaction was assessed by measuring hind paw thickness at the indicated times.

#### **6. Leukocyte separation**

Mononuclear leukocytes (MNL) and neutrophils were prepared by the rapid single-step separation method (11). Briefly, whole blood was layered onto Hypaque-Ficoll medium of density 1.114 and then centrifuged at 400g/30 min. After centrifugation, the leukocytes resolve into two distinct bands. The upper band contained MNL and the lower band the neutrophils.

#### **7. Lymphocyte proliferation**

Lymphocyte proliferation was measured by a semi-automated microtechnique (12). Human mononuclear cells ( $2 \times 10^5$ ) were seeded into u-bottomed wells of a microtitre plate (50  $\mu$ l) and treated with 50  $\mu$ l of the ethanol emu oil fraction. After 30 min incubation, 2  $\mu$ g/ $\mu$ l PHA was added to stimulate the T lymphocytes. The cells were incubated for 72h at 37°C in an atmosphere of 5% CO<sub>2</sub>-air and high humidity. At 6h prior to harvest, the cultures were pulsed with 1  $\mu$ Ci of <sup>3</sup>H-TdR. The cells were harvested and the amount of radioactivity incorporated measured in a liquid scintillation counter.

#### **8. Cytokine production**

Production of IL-2, IFN- $\gamma$  and lymphotoxin (TNF  $\beta$ ) by T lymphocytes was measured in MNL stimulated with PHA as described for lymphocyte proliferation. The supernatants from cell cultures were collected and the amount of cytokine measured by ELISA using cytokine specific monoclonal antibodies as described previously (13).

Production of the cytokine TNF  $\alpha$  by monocytes was measured in MNL stimulated with LPS. Briefly,  $2 \times 10^5$  MNL in a 100  $\mu$ l volume was added to flat bottomed wells of a microtitre plate and then the cells were stimulated by adding 100  $\mu$ l of 200ng/ml bacterial lipopolysaccharide (LPS). After incubation at 37°C/48h, the



supernatant was collected for TNF  $\alpha$  measurement, using an ELISA and TNF  $\alpha$  specific monoclonal antibody as described previously (13).

## 9. Neutrophil adhesion

### 9.1 To plasma coated surfaces

Adhesion was assessed by the ability of neutrophils treated with emu oil extract to bind to plasma-coated plates after stimulation with TNF  $\alpha$ . Plates which had been coated with autologous plasma (1:10), washed and dried received 50  $\mu$ l neutrophils ( $5 \times 10^6$ /ml) which were treated for 30 mins at 37°C/5% CO<sub>2</sub>. The neutrophils were stimulated with TNF  $\alpha$  ( $10^3$  units/ml) for 30 mins at 37 °C/5% CO<sub>2</sub>, washed with HBSS, then stained with 100  $\mu$ l Rose Bengal (0.25% w/v PBS) at room temperature. Non-adherent cells were removed by washing with HBSS, and then 200  $\mu$ l ethanol : PBS (1:1) was added and development proceeded at room temperature for 30 mins before reading on a plate reader at 570nm.

### 9.2 Neutrophil adherence to human umbilical vein endothelial cells (HUVEC).

HUVECs were isolated from umbilical cords stored at 4°C after delivery, as previously described (15) but with 0.2% (w/v) gelatin (Cytosystems) to coat all tissue culture flasks and plates, 0.07% (w/v) collagenase (from *Clostridium histolyticum*, type II, Worthington) to digest the interior of the umbilical vein, and a culture medium consisting of RPM1640 (ICN-Flow) containing 40 mmol/l TES, 15 mmol/l D-glucose, 80U/ml penicillin (Flow), 80  $\mu$ g/ml streptomycin (Flow), and 3.2 mmol/l L-glutamine, which was brought to 260 to 300 mOsm/l before the addition of 20% (v/v) pooled, heat-inactivated (56°C, 30 minutes) human group AB serum. Endothelial cells were identified by their characteristic contact-inhibited cobblestone morphology and positive staining for factor VIII-related antigen using peroxidase-conjugated anti-rabbit IgG to human von Willebrand factor (Dako) and 3,3'-diaminobenzidine.

Confluent cultures were subcultured after 2 to 5 minutes exposure to trypsin (0.05% [v/v], Flow)- EDTA (0.02% [w/v]). For experimental use, second-passage cells were plated at  $2 \times 10^6$  cells per well per 0.2ml culture medium in 96-well culture plates. The HUVECs were treated with the emu oil ethanol soluble fraction and then with TNF- $\alpha$ , the monolayers were washed once with RPMI 1640, before incubation for 30 minutes at 37°C in the absence or presence of  $5 \times 10^5$  neutrophils in E-SFM (final volume, 100 $\mu$ l). Nonadherent cells were removed by gentle aspiration, and the wells were washed twice with HBSS containing 0.1% (w/v)  $\mu$ M phorbol myristate acetate (PMA) to stimulate the cells' BSA before staining with rose bengal. After release of the dye with 50% ethanol, the absorbance (570nm) of each well was determined with an ELISA plate reader. Test and blank wells were performed in triplicate. Results were calculated after subtraction of the mean blank value ( without leukocytes) from each test value (plus leukocytes) (15).

#### 10. Neutrophil chemotaxis

Chemotaxis was measured by the migration under agarose method as previously described (16). Six millilitres of 1% molten agarose in medium 199 containing 5% fetal calf serum were poured into petri dishes. After the agarose solidified, sets of three holes/wells were punched in the agarose layer. Plates with these sets of three wells were used to measure leukocyte migration in a chemotaxis gradient, with 5 $\mu$ l of  $1 \times 10^{-7}$ M fMLP, 5 $\mu$ l of neutrophils ( $2.5 \times 10^5$ ) and 5 $\mu$ l of medium 199 being added to the inner, centre and outer wells respectively. Two well sets were used to measure random migration, cells being added to one well and medium to the other. The plates were incubated at 37°C and the distance of cell migration measured directly under a phase-contrast microscope after 90 min. The approximate migration distances of neutrophils in assays conducted in our laboratory were 2.2mm and 0.7mm in the presence and absence of fMLP, respectively.

#### 11. Results

##### 11.1 Chemical composition of emu oil

Analyses of emu oil were conducted at a number of different centres to enable a better assessment of the various constituents of the oil. Fatty acid analyses of emu

oils were made at the Women's and Children's Hospital in Adelaide, Flinders University, and at the Royal Melbourne Institute of Technology (RMIT), Victoria. Analysis of phenolic content of the oil was conducted at the University of South Australia and sterol analysis at RMIT. The results are all presented and, in some cases, comparisons between the same oils from analyses made at different centres are outlined.

### 11.2 Fatty acid composition of emu oils

Examination by thin layer chromatographic analysis of emu oil showed that the major component of emu oil is triacylglycerol. However, smaller amounts (around 1-2%) of at least 7 other minor components were detected (Fig 3). Three of these were tentatively identified as unesterified fatty acids, diacylglycerol, and sterols.

The identity of the other components was not established. Some of these had a similar chromatographic mobility to compounds present in olive oil. These experiments indicate that emu oil is a more complex mixture than previously believed. As many of the minor components in olive oil are thought to contribute to its properties, particularly its health benefits, it is likely that the minor components in emu oil may also have a similar effect. Apart from a band in olive oil running near the solvent and tentatively identified as the hydrocarbon, squalene, the chromatographic profile of emu oil did not appear very different from olive oil, although it is likely that there are some components that are unique to each oil.

The fatty acid composition of the nine emu oils analysed by GC-MS at Flinders University by Dr Neil Trout (organic chemist) is shown in Table 5. The predominant fatty acid was oleic acid (18:1 $\omega$ 9). This ranged from 49% to 58% of the fatty acids in the nine oils. The next most prominent fatty acid was palmitic acid (16:0), which ranged from 19-22%. Other prominent fatty acids were stearic acid (18:0) ranging from 9-11%, linoleic acid (18:2 $\omega$ 6) ranging from 5.5-17% and hexadecenoic acid (16:1 $\omega$ 7) ranging from 3-6%. A typical GC-MS trace of the fatty acid analyses is seen in Fig 4.

Table 5: GC-MS Analysis of nine preparations of emu oil. GC-MS analyses were performed on a Varian Saturn 4D instrument with a J&W DB5/phenylmethyl polysiloxane column (30m x 0.25mm).

Emu oil	fatty acid								
	14:0	14:1	16:0	16:1	17:0	18:0	18:1	18:2	20:0/20:1
Little Meadow	Trace	trace	20.18	5.79	trace	8.84	50.12 4.65 trace	10.40	trace trace
Toowoomba	Trace	trace	20.17	3.63	trace	11.60	49.12 3.23 trace	9.04	trace trace
Gut Fat A	Trace	trace	21.36	5.22	trace	10.45	48.87 4.89 trace	9.21	trace trace
G53	Trace	trace	20.13	3.88	trace	11.65	58.33 2.70 trace	2.79	trace trace
A2-100G	Trace	trace	19.48	3.98	trace	11.64	54.28 4.60 trace	5.45	trace trace
Makin	Trace	trace	18.92	3.53	trace	11.04	49.60 2.91 trace	14	trace trace
Back Fat A	Trace	trace	22.25	5.27	trace	10.92	49.31 3.86 trace	8.38	trace trace
Duncan 170M	Trace	trace	19.65	3.50	trace	10.13	52.32 3.26 trace	11.13	trace trace
Duncan 176M	trace	trace	19.20	2.85	trace	8.83	49.78 2.70 trace	16.70	trace trace

Analyses of these oils were also undertaken in Dr Bob Gibson's laboratory at Flinders University (Table 6). Nine emu oil samples were analysed by this method. Examination of GC traces showed that the fatty acid composition was much more complex than had been suspected, with upwards of two dozen different fatty acids identified. Many of these components were only present in trace amounts (< 0.1%). Emu oil contains mainly straight chain even numbered carbon chain fatty acids, the major saturates being palmitic (16:0) and stearic (18:0) acids, with only small amounts of shorter (14:0) and longer (20:0 and 22:0) chain saturates (Table 6).

Table 6 GC Analyses of emu oil fatty acids									
Fatty Acid	GC Peak	GC Peak	GC Peak	GC Peak	GC Peak	GC Peak	GC Peak	GC Peak	GC Peak
16:0	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:1	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:2	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:3	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:4	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:5	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:6	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:7	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:8	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:9	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:10	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:11	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:12	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:13	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:14	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:15	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:16	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:17	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:18	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:19	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:20	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:21	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:22	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:23	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:24	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:25	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:26	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:27	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:28	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:29	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:30	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:31	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:32	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:33	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:34	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:35	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:36	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:37	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:38	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:39	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:40	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:41	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:42	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:43	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:44	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:45	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:46	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:47	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:48	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:49	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:50	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:51	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:52	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:53	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:54	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:55	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:56	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:57	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:58	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:59	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:60	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:61	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:62	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:63	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:64	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:65	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:66	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:67	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:68	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:69	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:70	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:71	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:72	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:73	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:74	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:75	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:76	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:77	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:78	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:79	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:80	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:81	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:82	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:83	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:84	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:85	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:86	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:87	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:88	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:89	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:90	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:91	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:92	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:93	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:94	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:95	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:96	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:97	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:98	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:99	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
16:100	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03

The ranges for the predominant fatty acids were 18:1  $\omega$ 9 (47-53%), 16:0 (20-24%), 18:0 (8-11%), 18:2 $\omega$ 6 (8-12%) and 16:1 $\omega$ 7 (3-5%). Again, the greatest variability was seen in 18:2 $\omega$ 6 and 18:0. The main monoenoic acid was oleic acid (18:1 $\omega$ 9). Traces of shorter (16:1 $\omega$ 9) and longer chain (20:1 $\omega$ 9, 22:1 $\omega$ 9) monoenoic acids were detected.  $\omega$ 7 series monoenoic fatty acids were also present, the main one being 16:1  $\omega$ 7, which was present in significant amounts (around 3%). Only traces of odd numbered carbon chain fatty acids were detected. The main polyunsaturated fatty

acid was linoleic acid (18:2  $\omega$ 6). Traces of other  $\omega$ 6 series polyunsaturated fatty acids were present, and included gamma linolenic (18:3 $\omega$ 6), arachidonic (20:4  $\omega$ 6), and docosatetraenoic (22:4 $\omega$ 6) acids.  $\omega$ 3 Polyunsaturated fatty acids were minor components, the main one being alpha linolenic acid (18:3 $\omega$ 3), with only traces of 16, 20, and 22 carbon compounds. Conjugated linoleic acid (the 9, 11 isomer) was also detected, but only in very small amounts (<0.1%).

Fatty acid analysis was also carried out by Ms K. Murphy in the laboratory of Professor Andrew Sinclair at RMIT. Approximately 21 individual fatty acids were identified in the emu oils (Table 7). The dominant fatty acid class was the monounsaturated fatty acids (approximately 54-57%), followed by the saturated fatty acids (31-34%). Omega-6 fatty acids were the dominant polyunsaturated fatty acids identified, ranging from 8-12%, while omega-3 fatty acids were present at less than 2% of total PUFA.

Oleic acid (18:1 $\omega$ 9) was the dominant fatty acid in the emu oils (Table 7), ranging from 48.2% in the G53 emu oil to 49.2% in the Makin emu oil. Palmitic acid (16:0) was the next most dominant fatty acid (approximately 19-23%), followed by stearic acid (18:0) (10-11%), linoleic acid (18:2 $\omega$ 6) (8-12%) and hexadecenoic acid (cis16:1  $\omega$ 7) (3-4%). DHA predominated in the tuna oil, followed by 16:0, 18:1  $\omega$ 9, 18:0, EPA, and cis 16:1 $\omega$ 7. Olive oil was predominantly 18:1 $\omega$ 9 (78%), with a smaller percentage of 16:0 (11%) and 18:0 (3%).

Table 7 GC Analysis of fatty acids of emu, tuna and olive oils at RMIT

Fatty acid	Oil				
	Emu (Makin)	Emu (S3C)	Emu (K2)	Tuna	Olive
12:0	0	0.42	0.14	0.01	0
12:1	0	0	0	0.70	0
14:0	0.49	0.29	0.14	2.59	0
14:1	0.06	0.43	0	0.85	0
15:0	0	0.01	0	0.77	0
16:0	21.94	18.62	23.33	17.07	11.09
16:1 $\omega$ 7	0.12	0.15	0	0.28	0.05
16:1 $\omega$ 7c	3.13	3.00	3.61	3.31	0.66
17:0	0.12	0.22	0.04	1.85	0.03
17:1	0.06	0.03	0	0.86	0.03
18:0	11.32	11.0	9.53	6.27	2.87
18:1 $\omega$ 9	49.2	48.24	51.32	13.04	77.84
18:1 $\omega$ 7	1.77	2.09	2.42	2.17	1.66
18:2 $\omega$ 6	11.90	10.51	8.18	1.88	5.88
18:3 $\omega$ 3	0.75	0.89	1.61	0.54	0.16
18:4 $\omega$ 3	0	0	0	0.87	0
20:0	0.03	0.22	0.01	0	0.02
20:1 $\omega$ 11	0.07	0.53	0.07	0.60	0.01
20:1 $\omega$ 9	0	0	0	1.55	0
20:1 $\omega$ 7	0	0	0	0.12	0
20:2 $\omega$ 6	0.01	0.55	0	0.91	0
20:4 $\omega$ 6	0	0.17	0	2.59	0
20:3 $\omega$ 3	0	0	0	0.12	0
20:4 $\omega$ 3	0	0	0	0.60	0
20:5 $\omega$ 3	0	0	0	6.01	0
22:4 $\omega$ 6	0	0.62	0	1.86	0
22:5 $\omega$ 6	0	0	0	0.4	0
24:0	0	0.01	0	1.72	0
22:5 $\omega$ 3	0	0	0	1.14	0
22:6 $\omega$ 3	0	0	0	23.46	0

All figures are percent of total fatty acids present in the oil.

Examination of the GC/Mass spectrometric analysis of emu oil fatty acids by Dr. D. Johnson at the Women's and Children's Hospital confirmed that the main fatty acid components of emu oil were 14:0, 16:1, 16:0, 18:1, 18:2, 18:0, 20:0 and 20:1 (see Fig 4). However, two other components, labelled as peaks 1 and 2, were also detected. These were not present in analyses carried out by two other laboratories. Neither peak was positively identified as a fatty acid, even though the 74 mass ion, indicative of fatty acid esters, was detected in both and was particularly prominent in peak 2. Based on a comparison of the peak heights as compared to other fatty acid peaks, peak 2 constituted around 3-4% of the total fatty acids in one of the emu oil samples analysed (Makin) and 6-7% in the other (A2-100G).

To explore the possibility that these two components were hydroxy fatty acids, samples of emu oil were hydrolysed with benzene/methanol/1% sulphuric acid at 100°C for 2 hours. After extraction into hexane, samples of the hydrolysate were chromatographed on a TLC plate in hexane-ether-acetic acid (80:20:1) and the

zones were detected by exposure to iodine vapour. Although under these conditions there had been almost complete hydrolysis of the emu oil, there was no evidence for the presence of hydroxy fatty acids. The only components detected were normal (unhydroxylated) fatty acid esters together with small amounts of alkali-stable lipids. One other possibility is that peaks 1 and 2 were formed by acetylation of diacylglycerols. Most animal and plant fats, including emu oil, contain small amounts of diacylglycerol generally formed by the breakdown of triacylglycerols. This possibility has not been investigated further.

### 11.3 Sterol analysis

Approximately thirty sterols were present in the emu oils and tuna oil, while 28 sterols were present in the olive oil (Table 8). Of those, 15 sterols of the emu oils and 19 of the olive oil could not be identified with gas chromatography not linked to a mass spectrometer. Data has been presented as percentage of total sterols. Cholesterol was the major component of the sterol fraction of both Adelaide emu oil samples. It comprised 70% of the Makin and 55% of the G53 emu oil sterols respectively. A further 14 sterols were identified. The only other component present in significant amounts was 4, 23, 24-trimethyl-5 $\alpha$ -cholest-22E-en-3 $\beta$ -ol (3.7 and 7.1%).



Table 8 Sterol analyses of emu, tuna and olive oil

Sterol	Sample Oil (% of total sterols)				
	Emu (Makin)	Emu (G53)	Emu KM	Tuna oil	Olive oil
Total unidentified peaks	18	33	34	10	64
5 $\alpha$ -cholestane	0.5	0.3	0.2	0.5	1.1
24-nordehydrocholesterol	1	0.5	0.1	3.1	1.0
C26 sterol	0.6	0.1	2.3	0	3.2
Patinosterol	0.6	0.1	0.1	0	1.1
Trans-22-dehydrocholesterol	0.6	0.1	0	0.9	0
Cholesterol	70	55	43	85	5
Cholestanol	1.5	1.1	0.3	0	0
Desmosterol	0.9	0.6	1.2	0	0
Brassicasterol	0.9	0.1	1.7	0	0
24-methylenecholesterol	0.1	0	2.9	0	0.8
24-methylcholesterol	0.2	0.2	1.5	0	1.5
Stigmasterol	0.9	0.7	1.9	0	0
$\beta$ -sitosterol	0.7	1.3	0.8	0	2.1
Isotricosterol	0.2	0.6	0	0.1	0
4,23,24-Trimethyl-5 $\alpha$ -cholest-22E-en-3 $\beta$ -ol	3.7	7.1	10.0	0	1

All figures are percent of total sterol present in the oil.

A number of the other components, such as sitosterol, brassicasterol, and sitosterol, are plant sterols and therefore probably derived from the diet. A further 15 components, many of which are believed to be sterols, were also detected but they were not identified. These data provide further evidence for the complexity of emu oil and for the variability of its composition. The presence of plant sterols indicates that the concentration and composition of the minor components may be affected by diet.

Other sterols present in the Makin and G53 emu oils were an unidentified (UI) sterol eluting before cholesterol (5 and 13% respectively), an UI sterol eluting before 4,23,24-trimethyl-5 $\alpha$ -cholest-22E-en-3 $\beta$ -ol (5 and 5% respectively), and cholestanol (2 and 1% respectively). The unidentified peaks were present in all samples tested and cannot be identified until gas chromatography with mass spectrometry is applied.

There were also traces of several additional sterols, including 5 $\alpha$ -cholestane, 24-nordehydrocholesterol, C26 sterol, patinosterol, trans-22-dehydrocholesterol, desmosterol, brassicasterol, 24-methylenecholesterol, 24-methylcholesterol,

stigmasterol,  $\beta$ -sitosterol and isofucosterol (all  $\leq 1\%$ ).  $\beta$ -sitosterol was the major sterol in the olive oil sample (21%). The peak identified as cholesterol (5%) in the olive oil sample is unlikely to be cholesterol. There is a possibility that it could be a long chain alcohol (28:0) which runs very close to cholesterol.

Tuna oil was comprised mainly of cholesterol (85%).

#### 11.4 Polyphenol analysis

The highest concentration of phenolics was found in olive oil, with values as high as 708  $\mu$ moles per litre (Table 9). Levels were very low in a number of other plant oils (sunflower, canola, and soya bean oils). The Makin emu oil had levels of phenolics that were comparable to those detected in castor and peanut oils (25.0 vs 21.7 and 25.0 and 27.1 and 30.0  $\mu$ mol per litre) (Table 9). As phenolics are normally found in plants, it is likely that the emu oil phenolics are derived from dietary sources. The total phenolic fraction of olive oil and other dietary oils normally comprises a mixture of simple and complex phenols. Although the emu oil phenolics were not identified, it is likely that they include a mixture of compounds. Their presence is a further indication of the complexity of emu oil. In view of their powerful antioxidant properties, and their ability to modulate the activity of immune cells (17), it is possible that they contribute to anti-inflammatory activity of emu oil, either directly or synergistically with other components present in the oil.

Table 9: Phenolic content in a range of plant and animal oils/fats.

SAMPLE	Phenol concentration ( $\mu\text{mol/l}$ )
Canola Oil (No Frills)	0.0
Liquid Paraffin BP	0.0
Water	0.0
Sunflower Oil (Stubbs)	1.4
Canola Oil (No Frills)	1.4
Water	1.7
Sunflower Oil (Sunbeam)	5.7
Liquid Paraffin BP	8.3
Soya Bean Oil	8.6
Soya Bean Oil	8.6
Ghee	15.3
Emu Oil (Emu Fire)	13.3
Ghee	15.7
Emu Oil (Emu Fire)	18.3
Castor Oil BP	21.7
Castor Oil BP	25.0
Peanut Oil	27.1
Peanut Oil	30.0
Olive Oil (J. Laforgha, Young Trees 2000)	690.0
Olive Oil (J. Laforgha, Young Trees 2000)	708.6
Makin Emu Oil	25.0

## 12. Anti-inflammatory properties of emu oil

### 12.1 The effect of emu oil on the chronic inflammatory reaction

In these experiments, the Makin emu oil preparation was primarily used, as this had been prepared under "guided" conditions. The chronic inflammatory response was measured by the delayed type hypersensitivity reaction. This reaction is initiated by an antigen and elicited following antigen challenge at various sites. The response is characteristic of sensitised T lymphocytes, which mobilize and accumulate at the antigen challenge site. Such cells then cause the non-specific accumulation of other lymphocytes and a large infiltration of macrophages. This represents a significant model of the reactions seen in inflammatory diseases where tissue damage occurs. In these investigations, we used sheep red blood cells (SRBC) as the antigen for the delayed type hypersensitivity response. Mice were primed with SRBC subcutaneously and after 5 days challenged in the footpad with SRBC and the amount of swelling measured 24h later. In these investigations, the effects of emu oil on the inflammatory response were evaluated by injecting 50 $\mu\text{l}$  of the Makin emu oil intraperitoneally, three hours prior to the antigen challenge. The data presented in Fig 5 show that mice which had been pretreated with emu oil

developed a significantly depressed DTH response, thus showing that emu oil has anti-inflammatory activity.

This activity of emu oil was found to be proportionately decreased as the amount of emu oil injected was decreased (Fig 6). Thus, when 120 $\mu$ l was injected, there was approximately 70% suppression of the DTH response, compared to 25% with 30 $\mu$ l emu oil.

Several experiments were conducted to examine the reproducibility of the effects of Makin emu oil on DTH inflammation. The oil was administered in 50 $\mu$ l ip. The results presented in Table 10 show that, in all cases, the emu oil was active in suppressing the inflammatory response.

Table 10: Summary of experiments examining the effects of Makin emu oil on the DTH response

Experimental Number	% inhibition of DTH response (Mean $\pm$ SEM)
1	42.9
2	46.7
3	38.8
4	43.5
5	25.3
6	56.0
Mean $\pm$ SEM	42.2 $\pm$ 4.1

Mice were immunised subcutaneously with SRBC and 5 days later challenged with SRBC subcutaneously in the hind footpad. Three hours prior to challenge, the mice were treated with 50 $\mu$ l of emu oil ip. The DTH reaction was assessed by measuring the thickness of footpad swelling. Five mice per group were used in each experiment.

A commercial source of emu oil cream from Emu Oil Therapies (EOT) designated as C1 was tested. The ointment is for topical application and contains small amounts of eucalyptus and lavender oils. The cream was applied to the footpads of mice 1h prior to challenge with SRBC. The results presented in Fig 7 show that C1 was highly immunosuppressive, causing a 60% reduction in footpad swelling.

## **12.2 Comparison of the anti-inflammatory properties of different emu oil preparations**

The various emu oil preparations which had undergone chemical analyses were also compared in their ability to reduce the inflammatory response. Groups of mice were sensitised with SRBC and, 3h prior to antigen challenge, received one type of emu oil intraperitoneally. It is evident from the results presented in Fig 8 that Makin emu oil was the most effective. The others showed very poor anti-inflammatory activity.

## **12.3 Comparison of the pre and post antigen challenge treatment with emu oil**

The utility of a substance to treat an inflammatory reaction can be assessed on its ability to stop inflammation even after it has been elicited. This was examined for emu oil using the DTH model. In initial studies, experiments were conducted in which the emu oil pretreatment time was varied from 1 to 5h prior to challenge. Thus, SRBC primed mice were pretreated at 1,3 and 5h prior to SRBC challenge with 50µl of Makin emu oil intraperitoneally. The results showed that the oil was most effective if given 1h prior to challenge (Fig 9).

In further experiments, the effects of delaying treatment of mice with emu oil until 3h after challenge with SRBC on the development of the DTH reactions were examined. Investigations were set up to compare the effects of 3h pre-treatment versus 3h post-treatment in relation to antigen challenge. The results showed that Makin emu oil was just as effective if the treatment were delayed and, in fact, delayed treatment was significantly more suppressive than treatment given prior to challenge (Fig 10).

## **12.4 Effects of emu oil on acute inflammation**

Acute inflammation is dominated by neutrophils rather than T lymphocytes and macrophages, although the latter two cell types are also likely to have a role. This can be tested using an established model of carrageenan induced inflammatory

responses. This model was used to examine the effects of emu oil on acute inflammation. Mice were treated intraperitoneally with Makin emu oil 3h prior to receiving carrageenan into the hind footpad. The swelling was then measured 24h after the injection of carrageenan. The data showed that the oil was quite effective in depressing the carrageenan-induced inflammatory response (Fig 11). As per DTH reaction, comparison of pretreatment of mice for 1h, 3h, 5h showed 1h to be most effective (Fig 12).

Examination of emu oil post-treatment with respect to acute inflammation and carrageenan-induced inflammation showed that the delayed treatment was just as effective with this model in inhibiting inflammation (Fig 13). As with chronic inflammation, a greater degree of suppression of inflammation was seen.

#### **12.5 Effect of rendering temperature on emu oil chemical composition and anti-inflammatory activity**

Makin emu fat (EF) was subjected to heating at 40°C for 2h, the oil removed and the remaining fat subjected to heating at 60°C for 2h. After collection of the oil, the fat was heated at 80°C and the oil produced under this temperature collected.

The oils prepared under the three different rendering conditions were analysed by GC. The results are presented in Table 11.

Fatty Acid	20.0°C	20.0-20.5°C	20.5-21.0°C	21.0-21.5°C
4:0				
6:0				
8:0				
10:0				
12:0	0.01	0.02	0.03	0.01
14:0	0.42	0.39	0.37	0.36
16:0	0.07	0.03	0.02	0.03
Sum 14:0				
16:1	20.84	20.83	20.71	27.47
17:0	0.22	0.09	0.08	0.00
Sum 17:0				
18:0	1.12	0.12	0.40	7.90
20:0	0.21	0.10	0.19	0.00
22:0	0.03			
24:0				
Total Saturated	32.67	20.29	33.72	35.97
Sum 18:1	0.02			
Sum 18:2	0.82	0.23	0.23	0.22
Sum 18:3	0.10			
Sum 18:4	0.04			
Sum 18:5	0.00	0.23	0.23	0.23
Sum 18:6				
18:1				
18:2				
18:3				
18:4	0.09	0.14	0.13	0.16
18:5				
18:6				
19:0	0.15	0.10	0.10	0.11
20:1	2.90	0.71	0.51	0.00
22:1				
24:1				
26:1				
28:1				
30:1				
32:1				
34:1				
36:1				
38:1				
40:1				
42:1				
44:1				
46:1				
48:1				
50:1				
52:1				
54:1				
56:1				
58:1				
60:1				
62:1				
64:1				
66:1				
68:1				
70:1				
72:1				
74:1				
76:1				
78:1				
80:1				
82:1				
84:1				
86:1				
88:1				
90:1				
92:1				
94:1				
96:1				
98:1				
100:1				
102:1				
104:1				
106:1				
108:1				
110:1				
112:1				
114:1				
116:1				
118:1				
120:1				
122:1				
124:1				
126:1				
128:1				
130:1				
132:1				
134:1				
136:1				
138:1				
140:1				
142:1				
144:1				
146:1				
148:1				
150:1				
152:1				
154:1				
156:1				
158:1				
160:1				
162:1				
164:1				
166:1				
168:1				
170:1				
172:1				
174:1				
176:1				
178:1				
180:1				
182:1				
184:1				
186:1				
188:1				
190:1				
192:1				
194:1				
196:1				
198:1				
200:1				
202:1				

The results showed that the three preparations were almost identical in terms of composition of the major and minor fatty acids. When compared to other emu oil preparations, the composition of fat was similar.

The three oils were then tested for their effects on the carrageenan-induced inflammatory response. Mice were pretreated for 3h with 120μl of each of the emu oil preparations (40°C, 60°C or 80°C) and then treated with carrageenan in the hind paw. The results showed that, while all three inhibited the inflammatory reaction,

60°C rendering produced the most effective oil followed by 80°C (Fig 14). While the rendering temperature effects were also seen in the DTH reaction, it was the 80°C and 100 °C oil preparations which were most anti-inflammatory (Fig 15).

## 12.6 Activity of the ethanol soluble fraction of emu oil

The ethanol soluble component of Makin emu oil was prepared and examined for anti-inflammatory properties by using several *in vitro* parameters of inflammation. The ethanol soluble fraction was tested for ability to depress T lymphocyte, macrophage and neutrophil responses.

### 12.6.1 T lymphocyte responses

Makin emu oil was subjected to solubility in ethanol. This ethanol soluble oil fraction was then tested for ability to depress proliferation of mitogen stimulated human lymphocytes. The mononuclear cells were isolated from peripheral blood and pretreated for 30 min with dilutions of the fraction and then challenged with phytohaemagglutinin (PHA). Proliferation of lymphocytes was measured after 48 hours using <sup>3</sup>H-TdR incorporation as a marker for DNA synthesis.

Lymphocytes pretreated with the ethanol soluble fraction of emu oil showed marked inhibition of PHA-induced lymphoproliferation (Fig 16 ). This aspect has been repeated several times and similar results were obtained reproducibly. Table 12 shows the results from a number of experiments which have examined the effect of ethanol extracts of Makin emu oil on lymphoproliferation. Using this assay system, the ethanol fractions from oils rendered at 40°C, 60°C and 80°C were tested. Interestingly, 60°C and 80°C oils were more active than 40°C (Fig 17).



Table 12:

Summary of experiments examining the effects of various ethanol extractions of Makin emu oil on the lymphoproliferation response in human T lymphocytes stimulated with PHA. A volume of 50 $\mu$ l of purified T lymphocytes ( $4 \times 10^6$ /ml) was placed into a U-bottom well and an equal volume of ethanol or ethanol extract of Makin emu oil (final of 1% whole emu oil equivalent) was added to the wells. The cells were incubated at 37°C/5%CO<sub>2</sub>/humid atmosphere for 30 min before 100 $\mu$ l of 5% AB serum or 2 $\mu$ g/ $\mu$ l PHA (in 5% AB serum) was added to the wells. The wells were then incubated at 37°C/5%CO<sub>2</sub>/humid atmosphere for 48 hours. Six hours prior to harvesting, the cells were pulsed with 1 $\mu$ Ci of methyl-<sup>3</sup>H-thymidine. Incorporated radioactivity was measured using a  $\beta$  counter.

Experimental Number	% Inhibition of Lymphoproliferative Response
1.	84.3 $\pm$ 1.5
2.	84.2 $\pm$ 5.5
3.	85.0 $\pm$ 8.5
4.	99.9 $\pm$ 0.14
5.	99.75 $\pm$ 0.045
Mean $\pm$ sem	90.63 $\pm$ 3.76

Considering that Makin emu oil was found to be highly active in inhibiting DTH in comparison to G53 emu oil, the ethanol fractions from the two oil preparations were compared in their abilities to inhibit T lymphocyte proliferation induced by PHA. The data presented in Fig 18 show that, while Makin emu oil caused >90% inhibition of the T lymphocyte response, G53 emu oil produced only 50% inhibition of this response.

### 12.6.2 Monocyte function

Further experiments examined the effect of emu oil on cytokine production by T lymphocytes. As per lymphocyte proliferation assays, the mononuclear leukocyte fraction was pretreated with the Makin emu oil ethanol fraction and then stimulated with PHA. After 48h incubation, the supernatants were assessed for levels of the cytokines, IFN- $\gamma$ , TNF- $\beta$  and IL-2 (Fig 19).

The results showed that production of these cytokines, and in particular IFN- $\gamma$ , was inhibited. Monocytes prepared as the adherent fraction of mononuclear leukocytes were pretreated with Makin emu oil ethanol fraction and then stimulated with bacterial lipopolysaccharide (LPS). The effect on TNF- $\alpha$  production was assessed by measuring the cytokine in the cultured treated or untreated monocytes. The results showed that Makin ethanol fraction of emu oil was a poor inhibitor of LPS-induced cytokine production (Fig 20).

### 12.6.3 Neutrophil adherence

Since neutrophils are the main proponents of acute inflammation, investigations were conducted as to whether the ethanol soluble emu oil fraction affected neutrophil functional responses essential for neutrophil tissue influx and whether accumulation of neutrophils at inflammatory sites requires the adhesion of neutrophils to the endothelium of blood vessels. This adhesion can be promoted by upregulating integrins on the neutrophil surface, as well as adhesion molecules on the endothelial tissue.

In the first set of investigations, neutrophils were exposed to Makin emu oil ethanol fraction and then stimulated with phorbol myristate acetate (PMA). The results showed that the PMA-induced upregulation of neutrophil adhesion to plastic surfaces was depressed by treatment with this fraction of oil (Fig 21).

In the second set of investigations, human umbilical vein endothelial cells were exposed to the Makin emu oil ethanol fraction. The cells were washed and then stimulated with tumor necrosis factor (TNF) to upregulate the adhesion molecules. Fresh neutrophils were added to the endothelial cell monolayers and the degree of neutrophil adherence was quantified. The (TNF) stimulated endothelial cells showed enhanced neutrophil adhesion and this was significantly reduced in endothelial cell cultures which had been pretreated with the emu oil (Fig 22).

#### 12.6.4 Neutrophil chemotaxis

The ability of neutrophils to move into infection sites is dependent on their chemotactic response. In this investigation, the neutrophil chemotaxis response was quantified by measuring the degree of movement of neutrophils towards a chemotactic agent, the tripeptide fMLP. The data presented in Fig 23 show that neutrophils, which had been pretreated with Makin emu oil ethanol fraction, showed a poor chemotactic response.

#### 12.7 Further characterisation of the anti-T cell activity of emu oil

Preliminary studies have also shown that some of the unsaturated fatty acids found in emu oil inhibit T lymphocyte and mononuclear cell responses. Thus, our results show that 18:2 $\omega$ 6 is strongly inhibitory compared with 18:1 $\omega$ 9, 18:0 and 18:2 (Fig 24).

Since long chain fatty acids such as 18:2  $\omega$ 6 are suspected to be responsible for the anti T cell effects, it was interesting to see if the fatty acid binding proteins in serum could prevent the activity present within the ethanol fraction. The lymphocytes were pretreated with the Makin emu oil ethanol fraction in the presence and absence of 5% human blood group AB serum and then stimulated with PHA. The data in Fig 25 show that serum could prevent the inhibitory effects of the emu oil ethanol fraction on T lymphocytes.

Chemical analysis of the ethanol fraction of Makin emu oil by GC showed that the fatty acids were present in similar proportions to the whole oil (Table 13).

However, there was a small increase in 18:2 $\omega$ 6.

Table 15 GC Fatty acid analyses of ethanol extract of Makh emu oil

Fatty Acid	Whole oil	Ethanol soluble extract
8:0		
9:0		
10:0		
11:0		
12:0	0.00	0.08
13:0		
14:0	0.42	0.30
15:0	0.07	0.08
Sum 14:0		
16:0	20.64	18.31
17:0	0.22	0.19
Sum 18:0		
18:0	11.14	7.95
20:0	0.21	0.16
22:0	0.03	
24:0		
Total Saturated	32.67	27.39
Trans 16:1	0.03	
Trans 18:1w7	0.82	0.30
Trans 18:1w7	0.19	0.21
Trans 18:2	0.64	
Total Trans	0.88	0.51
10:1		
12:1		
13:1		
14:1	0.00	0.10
15:1		
16:1w9	0.15	0.18
16:1w7	2.65	4.08
17:1		
18:1w9	47.88	49.57
18:1w7	1.84	1.85
19:1	0.05	
20:1w11	0.08	
20:1w9	0.41	0.58
20:1w11		
21:1w9	0.02	0.14
21:1w7		
Total Monounsaturated	53.41	53.40
18:2w6	0.02	
20:2w6	0.03	
22:2w6	0.03	
24:2w6	48.53	49.28
24:2w7	4.78	5.99
Sum 18:2 CLA	0.05	0.05
Sum 24:2 CLA		
18:3w6	11.93	14.69
18:3w7	0.04	0.04
20:3w6	0.10	0.11
20:3w7	0.02	
20:4w6	0.09	0.21
22:4w6		
22:5w6	0.04	
22:5w7		
Total w6	12.24	15.01
16:2w9	0.08	
18:2w8	0.82	1.04
18:4w8		
20:2w8		
20:5w3		
22:4w7	0.04	
22:6w7		
Total w2	0.84	1.04

The ethanol soluble emu oil fraction was also subjected to TLC (analytical). This revealed seven bands (Fig 26). Interestingly, band 3 corresponded to 18:2  $\omega$ 6. A preparative run was also conducted and this is shown in Fig 27, revealing 8 fractions. These fractions were then tested for the ability to inhibit lymphocyte proliferation. The results showed that the major activity was associated with fractions 3/4 and 6, equalling fraction 3 (Fig 28). The other fractions had much less activity. Interestingly, fraction 3 corresponds to 18:2  $\omega$ 6 mobility.

### 12.8 Anti-inflammatory properties of emu oil triglyceride fraction

The ethanol insoluble fraction contains primarily the triglyceride component of the oil. This was tested for inhibiting activity on the DTH reaction. In these experiments, mice were treated with the triglyceride fraction of emu oil either 3h prior to antigen challenge or 3h post- challenge. The DTH response was significantly reduced to a similar extent as the whole oil when the triglyceride fraction was applied either prior to or post antigen challenge (Fig 29).

## REFERENCES

1. Kresina, T.F. (ed) Immune Modulating Agents. Marcel Dekker, New York, pp1-557, (1997).
2. Craig-Schmidt, M. Emu: premier oil bird. IFORM 8, 246-252 (1997).
3. Bennett, G. Observations principally on the Animal and Vegetable Products of New South Wales; Gatherings of a Naturalist in Australia. London. John Van Voorst, Paternoster Row; 1860.
4. Snowden, J.M. and Whitehouse, M.W. Anti-inflammatory activity of emu oils in rats. *Inflammopharmacology* 5,127-132 (1997).
5. Lopez, A., Sims, D.E., Ablett, R.F., Skinner, R.E., Leger, L.W., Lariviere, C.M., Jamieson, L.A., Martinez-Burnes, J.A. and Zawadzka, G.G., Effect of emu oil on auricular inflammation induced with croton oil in mice. *Am. J. Vet. Res.* 60(12):1558-1561 (1999).
6. Fein, E., Caputo, J. and Nagal, K. Therapeutic uses of emu oil. United States patent 5,472,713, issued 1995.
7. Whitehouse M.W., Turner A.G., Davis C.K.C. and Roberts M.S. Emu oil(s): a source of non-toxic transdermal anti-inflammatory agents in aboriginal medicine. *Inflammopharmacology* , 6, 1-8 (1997).
8. Ferrante, A, Rowan-Kelly, B. & Thong, Y.H. Suppression of the immunological responses in mice by treatment with amphotericin B. *Clin. & Exp. Immunol.* 38, 70-76 (1979).
9. Costabile, M., Hii, C.S.T., Robinson, B.S., Rathjen, D.A., Pitt, M.J., Easton, C., Miller, R.C., Poulos, A., Murray, A.W., and Ferrante, A. A novel long chain polyunsaturated fatty acid,  $\beta$ -oxa 21:3n-3, inhibits T lymphocyte proliferation, cytokine production, delayed type hypersensitivity, carrageenan-induced paw oedema reaction and selectively targets intracellular signals. *J. Immunol.* 167:3980-3987 (2001).
10. Fletcher, D., Kayser, V., & Guilbaud, G. Influence of timing of administration on the analgesic effect of bupivacaine infiltration in carrageenan-injected rats. *Anesthesiology* 84, 1129-1137 (1996).

11. Ferrante, A. & Thong, Y.H. Optimal conditions for the simultaneous purification of mononuclear and polymorphonuclear leukocytes from human blood by the hypaque-ficoll method. *J. Immun. Methods* 36, 109-117 (1980).
12. Ferrante, A., Rowan-Kelly, B. & Thong, Y.H. Inhibition of mitogen induced human lymphocyte responsiveness by polymixin antibiotics. *Int. Arch. Allerg. & Appl. Immunol.* 69, 279-281 (1982).
13. Staugas, R.E.M., Harvey, D.P., Ferrante, A., Nandoskar, M. and Allison, A.C. Induction of tumour necrosis factor and interleukin-1 by *Pseudomonas aeruginosa* and exotoxin A-induced suppression of lymphoproliferation, TNF, lymphotoxin, interferon gamma and interleukin-1 in human leukocytes. *Infect. Immun.* 60, 3162-3168 (1992).
14. Bates, E.J., Ferrante, A., Robinson, B., Smithers, L. and Poulos, A. Effect of fatty acid structure on neutrophil adhesion, degranulation and damage to endothelial cells. *Atherosclerosis*. 116, 247-259 (1995).
15. Huang, Z.H., Bates, E.J., Ferrante, J.V., Poulos, A., Robinson, B.S. and Ferrante, A. Inhibition of stimuli-induced endothelial cell intercellular adhesion molecule-1, E-selectin and vascular cellular adhesion molecule-1 expression by arachidonic acid and its hydroxy- and hydroperoxy-derivatives. *Circulation Research*. 80, 149-158 (1997).
16. Ferrante, A., Goh, D.H.B., Harvey, D.P., Robinson, B.S., Hii, C.S.T., Bates, E.J., Hardy, S.J., Johnson, D.W. and Poulos, A. Neutrophil migration inhibitory properties of polyunsaturated fatty acids: the role of fatty acid structure, metabolism and possible second messenger systems. *J. Clin. Invest.* 93, 1063-1070 (1994).
17. Visioli, F. and Galli, C. The effects of minor constituents of olive oil on cardiovascular disease: new findings. *Nutrition Reviews* 56, 142-147 (1998).

**THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:**

1. An assay system for grading a substance so as to assess, in a standardized manner, its anti-inflammatory activity, said assay system comprising:

- (i) injection of a suitable antigen into an appropriate body part of a mammal;
- (ii) either injection of a predetermined amount of said test substance into the same body part, or topical application to said mammal of a predetermined amount of said substance;
- (iii) measurement of the degree to which swelling which would otherwise result from injection of said antigen is reduced or alleviated; and
- (iv) comparing the activity of said test substance, as measured in step (iii), against the activity of a standard compound having known anti-inflammatory characteristics, the activity of said standard compound having been measured by this same assay system of steps (i) to (iii), and having been used to generate a grading system to compare the efficacy of various of the assessed substances.

2. An assay system for grading a substance so as to assess, in a standardized manner, its anti-inflammatory activity, said assay system comprising:

- (i) measurement of the activity of an *in vitro* preparation of T-cells, macrophages or neutrophils, or a cell line derived therefrom;
- (ii) addition of said substance to said preparation of T-cells, macrophages or neutrophils, or said cell line derived therefrom;
- (iii) measurement of the change in activity of said preparation of T-cells, macrophages or neutrophils, or said cell line derived therefrom, following addition of said substance in step (ii); and
- (iv) comparing the change in activity (as measured in step (iii)) for said substance against the change in activity for a standard compound having known anti-inflammatory characteristics, the change in activity for the standard compound having been measured by this same assay system of steps (i) to (iii), and having been used to generate a grading system to compare the efficacy of various of the assessed substances.



3. An assay system according to claim 1 or claim 2, wherein said substance is an oil or a fat, an organic solvent extract of an oil or a fat, a preparation comprising an oil or a fat, or a biologically active component of an oil or a fat.
4. An assay system according to claim 3, wherein said substance is selected from the group consisting of animal oils; plant oils, such as tea tree oil, flaxseed oil, linseed oil, borage oil and evening primrose oil; fish oils; and algal, microbial and fungal oils.
5. An assay according to claim 3 or claim 4, wherein said substance is emu oil or an ethanol extract of emu oil.
6. An assay system according to claim 1 wherein, in step (i), said antigen is injected intraperitoneally or into a footpad or ear of said mammal.
7. An assay system according to claim 1 or claim 6, wherein said antigen is Carrageenan or sheep red blood cells.
8. An assay system according to claim 1 wherein, in step (ii), said substance is injected intraperitoneally or applied topically.
9. An assay system according to claim 2, wherein said preparation is a preparation of T lymphocytes and said activity is lymphoproliferation.
10. An assay system according to claim 2, wherein said preparation is a preparation of T lymphocytes and said activity is production of cytokines.
11. An assay system according to claim 10, wherein said cytokines are selected from the group consisting of interleukin-2, tumor necrosis factors and interferon- $\gamma$ .

12. An assay system according to claim 2, wherein said preparation is a preparation of neutrophils and said activity is chemotaxis.
13. An assay system according to claim 2, wherein said preparation is a preparation of neutrophils and said activity is adherence to endothelial cells.
14. An assay system according to claim 1 or claim 2, wherein steps (i) to (iv) are repeated, using serially reducing amounts of said substance.
15. An assay system according to claim 14, wherein said substance is serially diluted in ethanol.
16. A pharmaceutical composition for treating or ameliorating the symptoms of a T-cell mediated disease or condition or a neutrophil mediated disease or condition in a mammal, said pharmaceutical composition comprising emu oil, or a biologically active extract or component thereof, optionally together with a carrier vehicle.
17. A pharmaceutical composition according to claim 16, wherein the disease or condition is immune complex disease, renal disease, nephritis, arthritis, glomerulitis, vasculitis, gout, urticaria, angioedema, cardiovascular disease, systemic lupus erythematosus, breast pain/premenstrual syndrome, asthma, neurological disease, attention deficit disorder (ADD), psoriasis, retinal disease, acne, sepsis, granulomatosis, inflammation, reperfusion injury, cystic fibrosis, adult respiratory distress syndrome, thermogenesis, diabetes, inflammatory bowel disease, Crohn's disease, multiple sclerosis (MS), systemic sclerosis, osteoarthritis, atopic dermatitis, allergic contact dermatitis, graft rejection (graft versus host disease) or transplantation.
18. A pharmaceutical composition according to claim 16 or claim 17, wherein said biologically active extract or component is selected from the group consisting of triglyceride fractions, triglyceride fraction components, sterol fractions, sterol

fraction components, phenolic fractions, phenolic fraction components, alkali-stable fractions, alkali-stable fraction components, organic solvent extracts, components of organic solvent extracts, and mixtures thereof.

19. A pharmaceutical composition according to any one of claims 16 to 18, being an oral, injectable or topical composition.

20. A pharmaceutical composition according to claim 19, being an injectable composition.

21. A method of treating or ameliorating the symptoms of a T-cell mediated disease or condition or a neutrophil mediated disease or condition in a mammal, said method comprising administration of an effective dose of a composition comprising emu oil, or a biologically active extract or component thereof.

22. A method according to claim 21, wherein the disease or condition is immune complex disease, renal disease, nephritis, arthritis, glomerulitis, vasculitis, gout, urticaria, angioedema, cardiovascular disease, systemic lupus erythematosus, breast pain/premenstrual syndrome, asthma, neurological disease, attention deficit disorder (ADD), psoriasis, retinal disease, acne, sepsis, granulomatosis, inflammation, reperfusion injury, cystic fibrosis, adult respiratory distress syndrome, thermogenesis, diabetes, inflammatory bowel disease, Crohn's disease, multiple sclerosis (MS), systemic sclerosis, osteoarthritis, atopic dermatitis, allergic contact dermatitis, graft rejection (graft versus host disease) or transplantation.

23. A method according to claim 21 or claim 22, wherein said biologically active extract or component is selected from the group consisting of triglyceride fractions, triglyceride fraction components, sterol fractions, sterol fraction components, phenolic fractions, phenolic fraction components, alkali-stable fractions, alkali-stable fraction components, organic solvent extracts, components of organic solvent extracts, and mixtures thereof.

24. A method according to any one of claims 21 to 23, wherein said composition is administered orally, parenterally or topically.
25. A method according to claim 24, wherein said composition is administered by injection.
26. Use of an organic solvent to extract compounds having anti-inflammatory activity from a biologically active oil or fat.
27. The use according to claim 26, wherein said biologically active oil is emu oil.
28. The use according to claim 26 or claim 27, wherein said organic solvent is an alcohol.
29. The use according to claim 28, wherein said alcohol is ethanol.
30. A method of preparing emu oil for therapeutic use, including the step of heating the emu oil, or the tissue from which the emu oil is derived, to a temperature of at least 40°C.
31. A method according to claim 30, wherein said temperature is about 60°C, about 80°C or about 100°C.

1/29




Fig 1. Results from Fig 6 (following) have been re-graphed to establish a relationship from which the inhibitory dose (ID<sub>25</sub>) of an emu oil can be derived. It remains to be noted that this assay is based on one injection of emu oil. It therefore represents an underestimation of the activity when applications for several days are being used.

2/29





Fig 2. A schematic representation of the cellular inflammation involved in joint cartilage damage in rheumatoid arthritis. During the disease the endothelium becomes activated and promotes the adhesion and movement of the leukocytes, T cells, neutrophils and monocytes (macrophages) into the joint. A network of intercellular signalling involving cytokines and other mediators, causes the changes of these inflammatory cells to a tissue destructive phenotype. Points of target by emu oil are shown by asterix. \*\* indicates strong inhibition and \* modest inhibition.

3/29



*Fig 3. The preparative separation of emu oil by thin layer chromatography (TLC). The oil preparation was loaded onto a silicone-coated TLC plate. The TLC was run in a solvent system consisting of diethylether:hexane:glacial acetic acid (20:80:1) until 1 cm from the margin. The plate was dried and samples covered with foil for protection and the zones developed by exposure to I<sub>2</sub> gas.*

4/29





Fig 4. GC-MS analysis of A2-100G emu oil. Trans-esterification of emu oil components was carried out at 90 °C for 90 min in benzene/acetylchloride/methanol.




5/29




*Fig 5. The effect of Makin emu oil on the DTH response. Mice were immunised with SRBC subcutaneously and then challenged with SRBC in the footpad after 5 days. Three hours prior to the challenge, the mice received 50 $\mu$ l of Makin emu oil intraperitoneally (ip). The reaction (footpad swelling) was measured 24 h after challenge by dial calliper. Controls received 50 $\mu$ l of saline. The data represent Mean  $\pm$  sem of 5 mice. The Mean  $\pm$  sem increase in footpad swelling of control was 0.75  $\pm$  0.02mm. Statistical analysis by Student's t-test, \*  $P < 0.0001$  for comparison between Control and Makin emu oil.*

6/29



*Fig 6. The effects of varying amounts of emu oil on the DTH response. Mice were immunized with SRBC subcutaneously and then challenged with SRBC in the footpad on day 5. Three hours prior to the challenge, the mice received various doses of Makin emu oil ip. The reaction was measured 24h after challenge by dial calliper. The data represent Mean  $\pm$  sem of 5 mice. The Mean  $\pm$  increase in the footpad swelling of control was  $1.17 \pm 0.10$ mm. Statistical analysis by Dunnett's test for multiple comparisons, \*  $P < 0.01$  for comparison between Control and tests.*

7/29



*Fig 7. The effect of a commercial emu oil cream (C1) on the DTH response. Mice were sensitised subcutaneously with SRBC and challenged 5 days later in the footpad. 1 hour prior to challenge, the mice received C1 emu oil applied topically to the footpads and tail. The footpad thickness was measured 3h after challenge by dial calliper. The results are the Mean  $\pm$  sem of 5 mice. The Mean  $\pm$  sem swelling of controls was  $0.7 \pm 0.04$  mm. Statistical analysis by Student's t-test, \*  $P = 0.0005$  for comparison between Control and commercial emu oil cream.*

8/29




Fig 8. The effect of various emu oil preparations on the DTH response. Mice were immunised with SRBC subcutaneously and then challenged on day 5 in the footpad. Three hours prior to challenge, the mice received 100 $\mu$ l of emu oil ip. The reaction was measured 24h after challenge by dial calliper. The data represent Mean  $\pm$  sem of 5 mice. The Mean  $\pm$  sem of control was 1.05  $\pm$  0.01 mm. Statistical analysis by Dunnett's test, \*P < 0.01 for comparison between Control and Makin emu oil.

NB GOLDING = LITTLE MEADOW

9/29




Fig 9. Effect of Makin emu oil pretreatment time on the DTH response. Mice were immunised with SRBC subcutaneously and then challenged with SRBC on day 6. Mice were treated ip with 50 $\mu$ l of Makin emu oil at 1, 3 or 5 h prior to challenge. The swelling of the footpad was measured 24h after challenge by dial calliper. Controls received 50 $\mu$ l of PBS. The data represent Mean  $\pm$  sem of 5 mice. The Mean  $\pm$  increase in footpad swelling of control was 1.03  $\pm$  0.07 mm. Statistical analysis by Dunnett's test for multiple comparisons, \* P < 0.05 for comparison between Control / 1h and Control / 3h pre-treatment times.

10/29






Fig 10. The effect of Makin emu oil pre-treatment and post-treatment on the DTH response. Mice were injected ip with 120 $\mu$ l of Makin emu oil either 4h before (pre-treatment) or 3h after (post-treatment) challenge. Control mice received PBS. The swelling of the paw was measured after 24h by dial calliper. The results are the Mean  $\pm$  sem of 5 mice. The Mean  $\pm$  sem of controls was 1.18  $\pm$  0.09mm. Statistical analysis by Student's t-test, \* P = 0.01 for comparison between Makin pre - treatment and Control and post-treatment and Control; \* P = 0.01 for comparison between Makin pre-treatment / post-treatment; \*\* P < 0.01 for comparison between Control and Makin post-treatment.

11/29



*Fig 11. The effect of Makin emu oil on the Carrageenan-induced paw inflammation. Mice were injected ip with 50 $\mu$ l of Makin emu oil. The animals were injected 3h later in the hind footpad with 25 $\mu$ l of 1% Carrageenan. Control mice received PBS instead of oil. The swelling of the paw was measured after 24h by dial calliper. The results are the Mean  $\pm$  sem of 5 mice. The Mean  $\pm$  sem of controls was 0.74  $\pm$  0.11mm. Statistical analysis by Student's *t*-test, \* *P* = 0.001 for comparison between Control and Makin emu oil.*

12/29



*Fig 12. The effect of Makin emu oil pretreatment time on Carrageenan-induced paw oedema. Mice were injected ip with 50 $\mu$ l of either Makin emu oil or PBS 1h, 3h, or 5h before injecting the hind footpad with 25 $\mu$ l of a 1% solution of Carrageenan in PBS. The swelling of the paw was measured after 3h by dial calliper. The results are the Mean  $\pm$  sem of 5 mice. The Mean  $\pm$  sem of controls was 0.7  $\pm$  0.07 mm. Statistical analysis by Dunnett's test for multiple comparisons, \*  $P < 0.01$  for comparison between Control and 1h pre-treatment time with Makin emu oil.*



13/29




Fig 13. The effect of Makin emu oil pretreatment and post-treatment on the Carrageenan-induced paw inflammation. Mice were injected ip with 120 $\mu$ l of Makin emu oil 3h before or 3h after challenge by injection of 1% Carrageenan into the hind footpad. Control mice received PBS. The swelling of the paw was measured after 24h by dial calliper. The results are the Mean  $\pm$  sem of 5 mice. The Mean  $\pm$  sem of controls were 0.9  $\pm$  0.17mm and 0.76  $\pm$  0.13mm respectively. Statistical analysis by Student's t-test, \*  $P = 0.04$  for comparison between Makin emu oil pre/post-treatment; \*\*  $P = 0.002$  for comparison between Control and Makin emu oil pre-treatment; \*\*\*  $P = 0.001$  for comparison between Control and Makin emu oil post-treatment.

14/29




Fig 14. The effect of temperature of rendering of emu oil on the Carrageenan-induced DTH response. Groups of mice were treated with 120 $\mu$ l of oil prepared in the laboratory by rendering fresh emu fat at 40°C, 60°C or 80°C respectively, 3h prior to injection with 25 $\mu$ l of 1% Carrageenan in PBS into the hind footpad. Control mice received PBS. The swelling of the footpad was measured after 24h. The results are the Mean  $\pm$  sem of 4 mice. The Mean  $\pm$  sem of controls was 0.83  $\pm$  0.07mm. Statistical analysis by Dunnett's test for multiple comparisons, \*P < 0.01 for comparison between Control and Makin emu oil rendered at 60°C and 80°C.

15/29




Fig 15. The effect of rendering temperature of emu oil produced in the laboratory on the DTH response. Oils were prepared on two separate occasions from an emu fat mixture sourced from both gut and back fat locations. Fresh emu fat was heated at 40°C for 2h and the oil collected. The fat remaining was then re-heated at 60°C and further oil collected. The process was repeated at 80°C. Each fraction of oil was tested on the DTH response. Mice were immunised with SRBC subcutaneously and then challenged with SRBC in the footpad after 5 days. Three hours prior to challenge, the mice received ip oil rendered at 40°C, 60°C or 80°C. The reaction was measured 24 h after challenge by dial calliper. Controls received 120µl of PBS. The data represent Mean  $\pm$  sem of 8 mice. The Mean  $\pm$  sem increase in footpad swelling of controls was  $1.21 \pm 0.17$  mm. Statistical analysis by Dunnett's test for multiple comparisons, \*  $P < 0.01$  for comparison between Control and Makin emu oil rendered at 80°C and 100°C.

16/29




Fig 16. Effect of ethanol extract of Makin emu oil on lymphoproliferation. To 50 $\mu$ l of purified T lymphocytes (  $4 \times 10^6$  /ml ) was added an equal volume of ethanol extract of Makin emu oil to the indicated final amount (%) equivalent of whole emu oil. The cells were incubated at 37°C / 5% CO<sub>2</sub> / humid atmosphere for 30min before 100 $\mu$ l of 5% AB serum or 2 $\mu$ g/ $\mu$ l PHA ( in 5% AB serum ) was added to the wells. The wells were then incubated at 37°C / 5% CO<sub>2</sub> / humid atmosphere for 48 h. Six hours prior to harvesting, cells were pulsed with 1 $\mu$ Ci of methyl-<sup>3</sup>H-thymidine. Incorporated radioactivity was measured using a  $\beta$  counter. The proliferation stimulation index in controls (absence of emu oil extract) was 44. Statistical analysis by Dunnett's test for multiple comparisons, \* P < 0.01 for comparison between Control and test samples.

17/29




Fig 17. The effects of rendering temperature on the anti-lymphoproliferative effects of emu oil prepared in the laboratory. Oils were prepared from emu back fat. A piece of fresh fat was heated at 40°C for 2h and the oil collected. The remaining fat was then heated at 60°C and further oil collected. The process was repeated at 80°C. Each fraction of oil was subjected to ethanol extraction and then tested for anti-lymphoproliferative activity. To a volume of 50 $\mu$ l of purified T lymphocytes at  $4 \times 10^6$ /ml was added an equal volume of the ethanol extract to give 1% final of the whole emu oil equivalent. The cells were incubated at 37°C/5% CO<sub>2</sub>/ humid atmosphere for 30min before 100 $\mu$ l of 5% AB serum or 2 $\mu$ g/ $\mu$ l PHA ( in 5% AB serum) was added to the wells. The wells were then incubated at 37°C/ 5% CO<sub>2</sub>/ humid atmosphere for 48h. Six hours prior to harvesting, cells were pulsed with 1 $\mu$ Ci of methyl - <sup>3</sup>H -thymidine. Incorporated radioactivity was measured using a  $\beta$  counter. The proliferation stimulation index in controls (absence of emu oil extract) was 147. Statistical analysis by Dunnett's test for multiple comparisons,  $P < 0.01$  for comparison between Control and test samples. Comparison by Tukey-Kramer Test for multiple comparisons, 40°C vs 60°C ( $P < 0.001$ ) and 40°C vs 80°C ( $P < 0.001$ ).

18/29





Fig 18. Comparison of the effects of ethanol soluble fractions from Makin and G53 emu oil on lymphoproliferation. Human peripheral blood mononuclear leukocytes (MNL) were treated with the fractions (equivalent to 1% of whole oil) of these two oils for 30 min and then stimulated with the T cell mitogen, phytohaemagglutinin (PHA). The cells were then incubated for a further 48 h and the degree of proliferation assessed by measuring the amount of  $^3\text{H}$  - thymidine incorporated. The results are mean  $\pm$  sem of three experiments. The proliferation stimulation index in controls (absence of emu oil extract) was 121. Statistical analysis, \*  $P < 0.01$  by Dunnett's test for multiple comparisons for comparison between Control and Makin emu oil.

19/29



*Fig 19. The effect of ethanol extract of Makin emu oil on cytokine production by T lymphocytes. A volume of 50 $\mu$ l of  $4 \times 10^6$ /ml of purified T lymphocytes was treated with 50 $\mu$ l of 1% (v/v) of Makin emu oil ethanol extract for 30min, stimulated with 100 $\mu$ l of 2 $\mu$ g/ml PHA in RPMI and incubated at 37°C / 5% CO<sub>2</sub> for 48h. The supernatants were collected and the various cytokines measured by ELISA. The stimulation index in controls (absence of emu oil extract) was 5.6. Statistical analysis by Dunnett's test for multiple comparisons, \* P < 0.01 for comparisons between Control and test samples.*

20/29




Fig 20. The effect of ethanol extract of Makin emu oil on production of TNF by human monocytes. To  $2 \times 10^5$  peripheral blood mononuclear cells was added 100 $\mu$ l of medium containing the extract to the indicated final amounts (% equivalent of whole emu oil) and the cells incubated for 30min at 37°C in an atmosphere of 5% CO<sub>2</sub>. The monocytes were stimulated by the addition of 100 $\mu$ l of 200ng/ml LPS in RPMI and incubated at 37°C / 5% CO<sub>2</sub> for 48h. The supernatant was collected and TNF measured by ELISA. The stimulation index in controls (absence of emu oil extract) was 8.



21/29




Fig 21. The effect of Makin emu oil ethanol fraction on adherence of neutrophils to plastic surfaces. An aliquot of 50 $\mu$ l of neutrophils (  $5 \times 10^6$  / ml ) was treated with 50 $\mu$ l of ethanol fraction at the indicated final amounts (%) equivalent of whole oil for 30min at 37°C/ 5% CO<sub>2</sub> on plates coated with autologous plasma. The cells were stimulated with TNF ( 125 units / ml ) for 30min at 37°C / 5% CO<sub>2</sub> and non-adherent cells were washed three times with HBSS and adherent cells were stained with Rose Bengal. The absorbance was read at 570nm. The stimulation index in controls (absence of emu oil extract) was 3. Statistical analysis by Dunnett's test for multiple comparisons, \*  $P < 0.01$  for comparison between Control and 1% Makin ethanol extract.

22/29




Fig 22. The effect of Makin emu oil ethanol extract on adhesion of neutrophils to HUVECS.  $2 \times 10^6$  HUVECS in 200 $\mu$ l were seeded in a 96 well plate and cultured for 2 days at 37°C / 5% CO<sub>2</sub>. On the day of use the cells were washed three times with 100 $\mu$ l HBSS. 100 $\mu$ l of fresh RPMI containing the ethanol extract (final of 1%, v/v whole oil equivalent) was added. Control wells received ethanol (1% v/v). The cells were incubated for 1h at 37°C / 5% CO<sub>2</sub>. Then PMA at final concentration of  $10^{-7}$ M in RPMI with 20% AB serum was added and incubated for 4h at 37°C / 5% CO<sub>2</sub>. The HUVECS were then washed three times with HBSS and 100 $\mu$ l of neutrophils at  $5 \times 10^6$ /ml added and incubated for 30min at 37°C. Non-adherent cells were washed with HBSS and adherent cells were stained with Rose Bengal and the absorbance read at 570nm. The stimulation index in controls (in the absence of emu oil extract) was 4. Statistical analysis by paired t-test, \*  $P < 0.05$  for comparison between Control and emu oil ethanol extract.

23/29





Fig 23. The effect of Makin emu oil ethanol extract on neutrophil chemotaxis.  $2 \times 10^6$  neutrophils were treated with an equal volume of 1% (v/v) Makin emu oil ethanol extract for 30min at  $37^\circ\text{C}$  / 5%  $\text{CO}_2$ . The cells were centrifuged and resuspended at a density of  $4 \times 10^7/\text{ml}$ . An agarose plate was set up with the following array in punched holes:  $5\mu\text{l}$  DMSO (0.1% v/v) was added to the inner wells,  $5\mu\text{l}$  fMLP ( $4 \times 10^{-7}$  M) was added to the outer wells and  $5\mu\text{l}$  treated or control neutrophils added to the centre wells and the plate incubated at  $37^\circ\text{C}$  / 5%  $\text{CO}_2$  for 90 min. Migration of the neutrophils towards fMLP containing wells was measured by inverted microscope. The stimulation index in controls (in the absence of emu oil extract) was 4.4. Statistical analysis by student t-test, \*  $P = 0.004$  for comparison between Control and Makin emu oil ethanol extract.

24/29



*Fig 24. Effects of 18:0, 18:1 $\omega$ 9 or 18:2 $\omega$ 6 on lymphocyte proliferation. Purified T cells or peripheral blood mononuclear cells (MNL) were preincubated with 20 $\mu$ M of stearic acid (18:0), oleic acid (18:1 $\omega$ 9) or linoleic acid (18:2 $\omega$ 6) for 30 min before being stimulated with PHA/PMA for 72 h. 6 h before the end of the incubation period, cells were pulsed with <sup>3</sup>H-thymidine. Following harvesting, the radioactivity incorporated into DNA was determined by liquid scintillation counting. Results are the means  $\pm$  sem of 3 experiments. A significant inhibition of T cell proliferation was seen only with 18:2 $\omega$ 6. Statistical analysis by Tukey-Kramer multiple comparison test, \*  $P < 0.001$  for comparison between fatty acid and Control for purified T cells and MNL. The proliferation stimulation index in controls (absence of fatty acids) was 207.*

25/29




Fig 25. The effect of serum on the Makin ethanol fraction-induced inhibition of lymphoproliferation. To 50  $\mu$ l of purified T lymphocytes ( $4 \times 10^6$ /ml) was added an equal volume of ethanol or 1%(v/v) ethanol extract of Makin emu oil made up either in RPMI 1640 containing 5% AB serum or in the absence of serum. The cells were incubated at 37°C/5% CO<sub>2</sub>/humid atmosphere for 30 min, before 100  $\mu$ l of 5% AB serum or 2  $\mu$ g/ $\mu$ l PHA (in 5% AB serum) was added to the wells. The wells were then incubated at 37°C/5% CO<sub>2</sub>/humid atmosphere for 48 h. Six hours prior to harvesting, cells were pulsed with 1  $\mu$ Ci of methyl-<sup>3</sup>H-thymidine. Incorporated radioactivity was measured using a  $\beta$  counter. The proliferation stimulation index of controls (absence of emu oil extract) was 242. Statistical analysis by Tukey-Kramer Multiple Comparisons Test, \*  $P < 0.001$  for comparison between PHA Control and stimulated Makin ethanol extract minus AB serum.

26/29




Fig 26. The separation of Makin ethanol extract by TLC. 100 $\mu$ g of 18:2 or Makin ethanol extract was spotted on to a TLC plate and dried under a stream of N<sub>2</sub>. The plate was then run in a solvent system (diethyl ether:hexane:glacial acetic acid, 60:40:1, v/v). The plate was allowed to dry and then exposed to I<sub>2</sub> vapour for identification of the zones.

27/29




Fig 27. The preparative separation of Makin ethanol extract by TLC. Total ethanol extract of Makin emu oil was spotted onto a TLC plate and dried under a stream of  $N_2$ . The plate was then run in a solvent system (diethyl ether:hexane:glacial acetic acid, 60:40:1, v/v). The plate was allowed to dry and then exposed to  $I_2$  vapour for identification of the zones.

28/29





Fig 28. The effect of TLC separated fractions of Makin ethanol extract on lymphoproliferation. Isolated lipid fractions were dissolved at a concentration of 20mg/ml in ethanol. To 100ml of  $4 \times 10^6$ /ml lymphocytes was added 50ml of ethanol emu oil extract to a final concentration of 1% equivalent of whole oil. Cells were incubated for 30 min in  $37^\circ\text{C}/5\% \text{CO}_2$  and then stimulated with  $2\mu\text{g}/\text{ml}$  PHA for 48 h. 6 h prior to harvesting, cells were pulsed with  $1\mu\text{Ci}$  of  $^3\text{H}$ -thymidine. Cells were harvested and incorporated radioactivity measured by liquid scintillation counting. The proliferation stimulation index in controls (absence of emu oil extract) was 133. Statistical analysis by Tukey - Kramer Multiple Comparisons Test, \*  $P < 0.001$  for comparisons between Control and TLC fractions.



29/29



*Fig 29. The effect of ethanol insoluble emu oil fraction (EIF) pre-treatment and post treatment on the DTH response. Mice were injected ip with 120 $\mu$ l of EIF either 4h before (pre-treatment), or 3h after (post treatment), challenge. Mice were challenged in the hind paw with SRBC 5 days after priming. Control mice received PBS. The swelling of the paw was measured after 24h by dial calliper. The results are the Mean  $\pm$  sem of 5 mice. The Mean  $\pm$  sem of controls was 1.0  $\pm$  0.08 mm. Statistical analysis by Dunnett's test for Multiple Comparisons, \*  $P < 0.05$  for comparisons between pre-treatment Control/ EIF and post-treatment Control / EIF.*

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU03/00266

**A. CLASSIFICATION OF SUBJECT MATTER**Int. Cl. <sup>7</sup>: G01N 33/15, 33/92; A61K 35/12, 45/06; C12Q 01/00; A61P 29/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

G01N 33/15, 33/92; A61K 35/12, 45/06, 49/00; C12Q 01/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPAT, JAPIO, CAPlus, Medline (antiinflammator\*; emu oil; t-cell/macrophage/neutrophil/cell line/t-lymphocyte; in vivo; in vitro; assay/screen/measure/test; swell\*)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Winter C.A. et al., (1962) <i>Proc. Soc. Exp. Biol. Med.</i> , vol. 111, pp. 544-547. "Carrageenin-induced edema in hind paw of the rat as an assay for antiinflammatory drugs". Whole document.	1, 3-8, 14, 15
X	Snowden J.M. and Whitehouse M.W. (1997) <i>Inflammopharmacology</i> , vol. 5, pp. 127-132. "Anti-inflammatory activity of emu oils in rats". Whole document.	1, 3-8, 14, 15
X	Hart, P.H. et al., (2000) <i>Inflammation Research</i> , vol. 49, pp. 619-626. "Terpinen-4-ol, the main component of the essential oil of <i>Melaleuca alternifolia</i> (tea tree oil), suppresses inflammatory mediator production by activated human monocytes". Whole document.	1-4, 6-11, 14, 15

☒ Further documents are listed in the continuation of Box C☒ See patent family annex

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search  
10 June 2003

Date of mailing of the international search report

17 JUN 2003

Name and mailing address of the ISA/AU

AUSTRALIAN PATENT OFFICE  
PO BOX 200, WODEN ACT 2606, AUSTRALIA  
E-mail address: pct@ipaustrialia.gov.au  
Facsimile No. (02) 6285 3929

Authorized officer

JULIE GALE

Telephone No : (02) 6283 2272

## INTERNATIONAL SEARCH REPORT

International application No. .

PCT/AU03/00266

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Lopez A. et al., (1999) <i>Am J Vet Res.</i> , vol. 60, pp. 1558-1561. "Effect of emu oil on auricular inflammation induced with croton oil in mice". Whole document.	1, 3-8, 14, 15
X	Whitehouse M.W. et al., (1998) <i>Inflammopharmacology</i> , vol. 6, pp. 1-8. "Emu oil(s): A source of non-toxic transdermal anti-inflammatory agents in aboriginal medicine". Whole document.	1, 3-8, 14, 15
X	Asuzu I.U. et al., (1999) <i>Phytomedicine</i> , vol. 6(4), pp. 267-272. "The antiinflammatory activity of <i>Icacina trichantha</i> tuber". Whole document.	1, 3, 4, 6-8, 14, 15
X	WO 92/08470 A1 (EMU PRODUCTS WESTERN AUSTRALIA PTY LTD) 29 May 1992 Whole document.	1, 3-8, 14, 15
X	US 6,346,278 B1 (Macrides et al.) 12 February 2002. Whole document.	1, 3-8, 14, 15
P,X	US 2003/0031724 A1 (Orthoefer et al.) 13 February 2003. Whole document.	1-6, 8, 10, 11, 14, 15

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU03/00266

**Box I** Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos :  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos : 26  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
The scope of claim 26 is so uncertain and broad that no meaningful search could be conducted on the subject matter.
3. ☐ Claims Nos :  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

**Box II** Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

See supplementary sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
The search is restricted to the invention as claimed in claims 1-15.

**Remark on Protest**

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU03/00266

**Supplemental Box**

(To be used when the space in any of Boxes I to VIII is not sufficient)

**Continuation of Box No: II**

This International Searching Authority considers that there are multiple inventions and the claims therefore lack unity of invention:

1. Claims 1-15 relate to assays for grading a substance so as to assess its anti-inflammatory activity. The assay can either be an *in vivo* screening assay or an *in vitro* screening assay. The assay as a whole can be regarded as representing a first "special technical feature".
2. Claims 16-20 relate to a pharmaceutical composition comprising emu oil or a biologically active extract or component thereof. Emu oil is a well known oil and it has various uses. The composition as claimed in claim 16 is not limited to use in treatment or amelioration of the symptoms of T-cell mediated disease or neutrophil mediated disease in a mammal. As emu oil is well known there is no "special technical feature" in claim 16 which could distinguish the composition from the prior art.  
Claims 21-25 relate to a method of treating or ameliorating the symptoms of a T-cell mediated disease or a neutrophil mediated disease in a mammal by administering emu oil. Claims 30 and 31 relate to the preparation of emu oil by heating the oil to a temperature of at least 40°C. A second "special technical feature" can be regarded as the preparation of emu oil for therapeutic use and a method of therapeutic use of emu oil.
3. Claims 26\*-29 relate to the use of an organic solvent to extract compounds having anti-inflammatory activity from a biologically active oil or fat wherein the organic solvent may be an alcohol. This represents a third "special technical feature".

The claims are not linked by a special technical feature which is common to all independent claims nor is there evidence that the claims relate to the same inventive concept. Since the above-mentioned groups of claims do not share any of the technical features identified, a "technical relationship" between the inventions (as defined in PCT rule 13.2) does not exist.

\* It is to be noted that claim 26 is considered by this International Searching Authority to be unsearchable. The scope of this particular claim is so broad that any search would be uneconomic. The claim encompasses the use of any organic solvent to extract compounds from any biologically active oil or fat, the extracted compounds having an anti-inflammatory property.

### Information on patent family members

**PCT/AU03/00266**

### Patent Document Cited in Search Report

END OF ANNEX